  Clinical Study Protocol 
    BTCRC-LUN15-029  
 
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients  with advanced 
NSCLC previously treated w ith PD-1 or PD-L1 Inhibitor:  
Big Ten Cancer Research Consortium BTCRC-LUN15-029  
 
Sponsor Investigator 
Greg Durm, MD 
Assistant Professor, Departmen t of Medicine, IU School of Medic ine 
Indiana University Health Simon Cancer Center 
  
Co-Investigators 
Nasser Hanna, MD 
Lawrence Einhorn, MD 
Shadia Jalal, MD 
Christina Ferreira, PhD 
Tiago Sobreira, PhD 
  
Statistician 
Susan Perkins, PhD 
  
Trial Management Provided by  
Big Ten CRC Administrative Headqu arters at Hoosier Cancer Resea rch Network, Inc. 
500 N. Meridian, Suite 100 
Indianapolis, IN 46204 
  
Trial Supported by  
Merck Sharp & Dohme Corp. 
(MISP 53940) 
  
Investigational New Drug (IND) Number: 
132237 
  
Initial Protocol Version Date:  26JAN2017  
 Protocol Amendment Version Date:  22MAR2017 26JUL2017  24JAN2019  07NOV2019 (current)  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 2 of 66 PROTOCOL SIGNATURE PAGE 
 
A Phase II Trial of Chemothera py plus Pembrolizumab in patients  with advanced NSCLC previously 
treated with PD-1 or PD-L1 Inhibitor: 
Big Ten Cancer Research C onsortium BTCRC-LUN15-029 
 
VERSION DATE:  07NOV2019 
I confirm I have read this pr otocol, I understand it, and I wil l work according to this protocol and to the 
ethical principles stated in the  latest version of the Declarat ion of Helsinki, the a pplicable guidelines for 
good clinical practices, whichever provides the greater protect ion of the individual.  I will accept the 
monitor’s overseeing of the study.  I will promptly submit the protocol to applicable ethical review 
board(s).  
 
  ____________________________________ ________________________ 
 S i g n a t u r e  o f  S i t e  I n v e s t i g a t o r        D a t e    ____________________________________  Site Investigator Name (printed)   
____________________________________ 
 Site Investigator Title   ____________________________________  Name of Facility   ____________________________________  Location of Facility (City and State)    
PLASE E-MAIL COMPLETED FORM TO BIG TEN CRC  
ADMINISTRATIVE HEADQUARTERS 
   
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 3 of 66 SYNOPSIS  
TITLE A Phase II Trial of Chemothera py plus Pembrolizumab in patients  with 
advanced NSCLC previously treat ed with PD-1 or PD-L1 Inhibitor:  
Big Ten Cancer Research Cons ortium BTCRC-LUN15-029 
SHORT TITLE Phase II Trial of Continuation P embrolizumab i n NSCLC: BTCRC-
LUN15-029
PHASE  2 
OBJECTIVES Primary Objective:  
 To assess if continuation therapy with pembrolizumab in 
combination with next-line ch emotherapy will improve PFS in 
patients who have previously be nefitted from a PD-1/PD-L1 
inhibitor (CR, PR, or SD ≥ 3months) according to RECIST 1.1 criteria as compared t o historical controls 
Secondary Objectives: 
 To estimate PFS by immune-rela ted RECIST (irRECIST) 
 To estimate objective respons e rate (ORR) by RECIST 1.1 and 
irRECIST 
 To estimate clinical benefit rate as defined by RECIST 1.1 and 
irRECIST 
 To estimate overall survival (OS) 
 Toxicity of pembrolizumab i n combination with next-line 
chemotherapy (gemcitabine, doc etaxel, or pemetrexed-non-
squamous only) 
Exploratory Objectives: 
 To assess tumor PD-L1 status at ba seline (prior to initial trea tment 
with PD-1 inhibitor) , at time of progression on PD-1 or PD-L1 
inhibitor (study entry), and at time of progression on combinat ion of 
pembrolizumab and chemothera py (safety follow up visit) 
 To correlate ORR, PFS, and clinical  benefit rate with the resul ts of 
proteomic analysis a nd lipidomic profiling 
 To correlate ORR, PFS, and clinical  benefit rate with the resul ts of 
NeoTYPE Lun g Tumor Profile Genetic Anal ysis 
STUDY DESIGN Single Arm Phase II 
KEY ELIGIBILITY 
CRITERIA   Histological or cytological evid ence of stage IV non-small cell  lung 
cancer (any histology) 
 Subjects must have pr ogressed on or after re ceiving platinum-ba sed 
chemotherapy. Chemotherapy may hav e previously been given with 
a PD-1 or PD-L1 inhibitor. The y must also have progressed on or  
after any PD-1 or PD-L1 inhibito r (including pembrolizumab) as 
their most recent therapy and m ust have had at least a 3-month PFS 
on this therapy. 
 Subjects must be enrolled on the  trial within 12 weeks of their  last 
infusion of PD-1 or PD-L 1 inhibitor therapy. 
 Demonstrates adequate organ f unction (as defined in Table 1) an d 
performance status (PS 0 or 1)
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 4 of 66  Must be fit enough to receive next -line chemotherapy (either 
gemcitabine, docetaxel, or pe metrexed [non-squamous only]) 
according to the discretion of  the treating physician. 
 Subjects whose tumors harbor  a mutation in EGFR exon 19 or 21 o r 
have gene rearrangements in ALK or  ROS1 must have already been 
treated with standard targeted t herapies. NOTE: Subjects must a lso 
have progressed on or after plati num-containing combination 
chemotherapy. 
 No evidence of active autoim mune disease requiring systemic 
treatment within the past 90 da ys or a documented history of 
clinically severe autoimmune di sease, or a syndrome that requir es 
systemic steroids or i mmunosuppressive agents. 
 No history of interstitial lung disease or pneumonitis related to the 
use of immunotherapeutic drugs. S ubjects with a history of 
pneumonitis which is unrelated t o the used of immunotherapeutic  
drugs may participate at the  discretion of the treating physici an 
 No history of an immune-related t oxicity requiring treatment wi th 
corticosteroids durin g prior PD-1 /PD-L1 inhibito r treatment.
STATISTICAL 
CONSIDERATIONS When the sample size is 31, a non- parametric tes t of median sur vival 
with a one-sided 0.05 significance level will have 80% power to  detect 
the difference between a median survival of 3 months vs 6 month s 
assuming an accrual period of appr oximately 6 months (6 per mon th) and 
maximum follow-up of 1.5 years. To a llow for replacement of pat ients 
who are not evaluable for effic acy (estimated to be 10%), up to  35 
patients will be enrolled.  
 The historical control is a m edian PFS of 3 months (in the 2nd/3rd 
line setting).  
 Null hypothesis - Pembrolizumab pl us chemo will have a median 
PFS of 3 months.  
 Alternative hypothesis –Pembroliz umab plus chemo will have a 
median PFS of 6 months  
Median PFS will be estimated u sing Kaplan-Meier methodology and  
tested using a non-parametric t est.  ORR and clinical benefit r ate will be 
estimated with two-sided 95% exact  binomial confidence interval s.  
Toxicities will be tabulated.  Change in tumor levels of PD-L1 will be 
descriptively summarized and com pared over time using paired t- tests.  
Proportional hazards regression (for PFS) and logistic regressi on (for 
ORR and clinical benefit rate) w ill be used to correlate proteo mic, 
lipidomic and genomic results with clinical outcomes. 
TOTAL NUMBER OF 
SUBJECTS  N = 35 
ESTIMATED 
ENROLLMENT PERIOD 12 months 
ESTIMATED STUDY DURATION  30 months 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 5 of 66 TABLE OF CONTENTS 
 
Schema ........................................................ ............................................................... ................................. 7 	
1.	Background and Rationale ...................................... ............................................................... ............. 8 	
1.1	Lung Cancer Background ........................................ ............................................................... .... 8	
1.2	Current Standard of Care for N on-Small Cell Lung Cancer ....... ................................................ 8 	
1.3	Background for Pembrolizumab .................................. ...............................................................  9	
1.4	Rationale ..................................................... ............................................................... ............... 12 	
2.	Study Objectives and Endpoints ................................ ............................................................... ........ 14	
2.1	Objectives .................................................... ............................................................... .............. 14 	
2.2	Endpoints ..................................................... ............................................................... .............. 14 	
3.	Eligibility Criteria .......................................... ............................................................... .................... 15 	
3.1	Inclusion Criteria ............................................ ............................................................... ........... 15 	
3.2	Exclusion Criteria ............................................ ............................................................... .......... 16 	
4.	Subject Registration .......................................... ............................................................... ................. 18 	
5.	Treatment Plan ................................................ ............................................................... ................... 18 	
5.1	Pre-medication and Hydration .................................. ............................................................... . 18	
5.2	Chemotherapy + Pembroliz umab Administration ................... ................................................. 18 	
5.3	Concomitant Medications ....................................... ............................................................... ... 19	
5.4	Supportive Care ............................................... ............................................................... .......... 21 	
5.5	Diet/Activity/Other  Considerations ............................ .............................................................. 23	
6.	Toxicities and Dose Delays /Dose Modifications ................. ............................................................. 2 4	
6.1	Dose Delays/Dose Modifications ................................ ............................................................. 2 4	
6.2	Dose Modifications ............................................ ............................................................... ........ 25	
6.3	Protocol Therapy Discontinuation .............................. .............................................................. 33	
6.4	Protocol Discontinuation ...................................... ............................................................... ..... 33	
7.	Study Calendar & Evaluations .................................. ............................................................... ......... 34 	
7.1	Screening Evaluations ......................................... ............................................................... ....... 36	
7.2	On Treatment Evaluations ...................................... ............................................................... ... 37	
7.3	Safety Follow-up Evaluations .................................. ............................................................... .. 38	
7.4	Long Term Follow-up Evaluations ............................... ............................................................ 38 	
8.	Biospecimen Studies and Procedures ............................ ............................................................... .... 38	
8.1	Tissue for assessment  of PD-L1 status ......................... ............................................................ 38 	
8.2	Tissue for genetic analysis ................................... ............................................................... ...... 39	
8.3	Blood for Somatic Baseline DNA ................................ ............................................................. 3 9	
8.4	Blood for proteomic analysis  and lipidomic profiling .......... .................................................... 39 	
8.5	Confidentiality of  Biospecimens ............................... ............................................................... . 39	
8.6	Samples for future studies .................................... ............................................................... ...... 39	
9.	Criteria for Disease Evaluation ............................... ............................................................... ........... 39 	
9.1	Measurable Disease ............................................ ............................................................... ....... 39	
9.2	Non-measurable Lesions ........................................ ............................................................... .... 40	
9.3	Target Lesions ................................................ ............................................................... ............ 40 	
9.4	Non-target Lesions ............................................ ............................................................... ......... 40 	
9.5	Evaluation of Target Lesions .................................. ............................................................... ... 40	
9.6	Evaluation of Non-target Lesions .............................. ...............................................................  41	
9.7	Evaluation of Best Overall Response ........................... ............................................................ 41 	
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 6 of 66 9.8	Definitions for Response Ev aluation – RECIST 1.1 .............. .................................................. 42 	
9.9	Immune- Related RECIST Criteria ............................... ............................................................ 43 	
10.	Drug Information .............................................. ............................................................... ................. 45 	
10.1	Pembrolizumab ................................................. ............................................................... ......... 45 	
10.2	Docetaxel ..................................................... ............................................................... .............. 48 	
10.3	Pemetrexed Disodium Heptahydrate (Alimta) ..................... ..................................................... 49 	
10.4	Gemcitabine ................................................... ............................................................... ............ 50 	
11.	Adverse Events ................................................ ............................................................... .................. 52 	
11.1	Definitions.................................................... ............................................................... .............. 52 	
11.2	Reporting...................................................... ............................................................... .............. 53 	
12.	Statistical Methods ........................................... ............................................................... .................. 56 	
12.1	Study Design .................................................. ............................................................... ............ 57 	
12.2	Endpoints ..................................................... ............................................................... .............. 57 	
12.3	Sample Size and Accrual ....................................... ............................................................... .... 57	
12.4	Analysis Datasets ............................................. ............................................................... .......... 57 	
12.5	Assessment of Safety .......................................... ............................................................... ....... 58	
12.6	Assessment of Efficacy ........................................ ............................................................... ...... 58	
12.7	Data Analysis Plans ........................................... ............................................................... ........ 58	
12.8	Interim Analysis/Crite ria for Stopping Study .................. ......................................................... 59 	
13.	Trial Management .............................................. ............................................................... ................ 59 	
13.1	Data and Safety Monitoring Plan (DSMP) ........................ ....................................................... 59 	
13.2	IUSCC Data Safety Monitoring Com mittee and Protocol Progress Co mmittee ...................... 59 	
13.3	Data Quality Oversight Activities ............................. ............................................................... . 60	
13.4	Compliance with Trial Registrat ion and Results Posting Requirem ents .................................. 60 	
14.	Data Handling and Record Keeping .............................. ............................................................... .... 61	
14.1	Data Management ............................................... ............................................................... ....... 61	
14.2	Case Report Forms and Submission .............................. ........................................................... 61 	
14.3	Record Retention .............................................. ............................................................... ......... 61 	
14.4	Confidentiality ............................................... ............................................................... ............ 61 	
15.	Ethics......................................................... ............................................................... ......................... 62 	
15.1	Institutional Review B oard (IRB) Approval ..................... ........................................................ 62 	
15.2	Ethical Conduct of the Study .................................. ............................................................... ... 62	
15.3	Informed Consent Process ...................................... ............................................................... ... 62	
16.	References .................................................... ............................................................... ...................... 63 	
Big Ten Cancer Research Consor tium    Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 7 of 66 SCHEMA 
 
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients  with advanced 
NSCLC previously treated w ith PD-1 or PD-L1 Inhibitor:  
Big Ten Cancer Research Consortium BTCRC-LUN15-029  
 
                   
 
                 Subjects with progressive diseas e on single-agent PD-1 or PD-L1  
inhibitor followin g at least 3 month PFS
Pembrolizumab 200mg IV every 21 days 
+ 
Physician’s choice chemot herapy with one of the 
following every 21 days: 
 Docetaxel 60-75mg/m2 IV  
 Pemetrexed 500mg/m2 IV (non-squamous only) 
 Gemcitabine 1000mg/m2 IV on days 1 and 8  *Optional 
biopsy 
recommended Enroll on study within 12 weeks of last 
PD-1 or PD-L1 infusion* 
Continue therapy unt il progression or 
unacceptable toxicity* 
*Optional biopsy 
at discontinuation 
is recommende d
Follow for overall survival 

Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 8 of 66 1. BACKGROUND AND RATIONALE 
1.1 Lung Cancer Background 
Lung cancer remains the leading cause of cancer-related  mortal ity in the United States with an 
estimated 224,390 new cases a nd 158,080 deaths in 2016 (1). Non -small cell lung cancer makes 
up approximately 83% of these cases  with several histologic sub types including adenocarcinoma, 
squamous cell carcinoma, large  cell carcinoma, and a few others  which are much less common 
(2). While a number of new tre atments have become available ove r the last decade, the 5-year 
overall survival (OS) rate for a ll lung cancer patients remains  poor at 17% and the OS for 
patients with metastatic disease is only 4% (2). New treatment options and approaches are 
needed to improve upo n these poor outcomes. 
1.2 Current Standard of Care for Non-Small Cell Lung Cancer 
The current standard of care fo r non-squamous NSCLC depends in large part on whether 
targetable mutations exist whic h can be exploited. Initial biop sy specimens are sent for 
mutational analysis with partic ular attention to activating epi dermal growth factor receptor 
(EGFR) mutations in exon 19 and 21or  gene rearrangements in eit her anaplastic lymphoma 
kinase (ALK) or ROS1. Tumors wh ich harbor sensitizing EGFR muta tions are responsive to a 
number of EGFR tyrosine kinase i nhibitors (TKI) including erlot inib, gefitinib, and afatinib, and 
use of one of these agents is recommended in the 1st line setting. ALK translocations should be 
treated with crizotinib in the 1st line setting and either ceri tinib or alectinib in the 2nd line setting 
(3). ROS1 mutations can be tre ated with crizotinib in the 1st line setting, and there is some 
evidence that cabozantinib may be  an active altern ative when re sistance develops to this therapy 
(4, 5).  In the majority of pat ients, there are no m utations for which t argeted therapies have been 
approved. In this setting, the standard of care remains chemoth erapy with a platinum doublet for 
fit patients. These combinati ons produce response rates of appr oximately 25-35% and 1-year OS 
rates of 30-40%. In non-squamous  histologies, bevacizumab may a lso be added to either 
cisplatin or carboplatin with peme trexed or to carboplatin and paclitaxel in patients without 
contraindications. Maintenance therapy with peme trexed, bevaciz umab, or erlotinib can also be 
considered in eligib le patients (3). 
 In the 2
nd line setting, the mai nstay of therapy has p reviously been sing le-agent chemotherapy 
with an agent not used as part of  initial therapy. The most com monly used medications include 
docetaxel, pemetrexed (only for  non-squamous), a nd gemcitabine.  Erlotinb was a lso previously 
approved in this setting though subs equent studies have shown t he majority of its activity to be in 
patients harboring activating mutations in EGFR, and its use fo r EGFR wild-type patients has 
declined. Recently, a trial of ram ucirumab, a monoclonal antibo dy against the vascular 
endothelial growth factor recept or 2 (VEGFR2), in combination w ith docetaxel showed a modest 
improvement in PFS and OS compar ed with docetaxel alone, though  there was also a modest 
increase in toxicity (6). One of  the most promising new therape utic strategies for advanced and 
metastatic NSCLC is the emerge nce of immunotherapy, particularl y programmed death-1 (PD-1) 
and programmed death ligand-1 (PD-L 1) blockade. In two separate  phase III trials, nivolumab, a 
PD-1 inhibitor, improved OS in both squamous and non-squamous p opulations when compared 
to single-agent docetaxel ( 7, 8). A second PD-1 inhibitor, pemb rolizumab, also showed good 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 9 of 66 activity in advanced and metasta tic NSCLC with >50% PD-L1 expre ssion on tumor cells with 
superior OS when compared wit h Docetaxel (9). In addition to th eir efficacy, both nivolumab 
and pembrolizumab were well tole rated during these trials with side effect profiles that are 
generally considered more manageab le than standard chemotherapy  options. Most importantly, 
there is the potential for durab le responses with these agents which gives hope for long-term 
survival in a patient population f or which this has typically b een rare (7-10). Given the 
improvements in OS, potential for  durable responses, and favora ble toxicity profiles, these drugs 
were approved by the FDA for the treatment of NSCLC following p rogression on a platinum 
doublet, and they are increasingl y considered the best option f or the 2nd line treatment of 
advanced and metastatic disease.  Following progression on either ni volumab or pembrolizumab, 3
rd line treatment for fit patients 
typically consists of single-ag ent chemotherapy. Typical regime ns include docetaxel with or 
without ramucirumab, gemcitabine , or pemetrexed in patients wit h non-squamous histology. 
Erlotinib can also be considered as a single agent in this sett ing. For patients who initially 
respond or have stable disease on immunotherapies, it is curren tly unclear whether continuation 
of these medications at the ti me of progression has any benefit  in the 3rd line setting. 
1.3 Background for Pembrolizumab 
1.3.1 Pre-clinical Data 
The importance of intact functions of immune surveillance in co ntrolling outgrowt h of neoplastic 
transformations has been known for decades (11). Accumulating e vidence shows a correlation 
between tumor-infiltrating lymphocy tes in cancer tissue and fav orable prognosis in various 
malignancies. In particular, the p resence of CD8+ T-cells and t he ratio of CD8+ effector T-
cells/FoxP3+ regulatory T-cells ( T-regs) correlates with improv ed prognosis and long-term 
survival in solid malignancies , such as ovarian, colorectal, an d pancreatic cancer; hepatocellular 
carcinoma; malignant m elanoma; and renal cell carcinoma. Tumor- infiltrating lymphocytes can 
be expanded ex vivo and re-infu sed, inducing durable objective tumor responses in cancers such 
as melanoma (12, 13).  The PD-1 receptor-ligand interact ion is a major pathway hijacke d by tumors to suppress immune 
control. The normal function of P D-1, expressed on the cell sur face of activated Tcells under 
healthy conditions, is to down- modulate unwanted or excessive i mmune responses, including 
autoimmune reactions. PD-1 (encoded by the gene Pdcd1 ) is an immunoglobulin (Ig) 
superfamily member related t o cluster of differentiation 28 (CD 28) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) th at has been shown to negatively  regulate antigen receptor 
signaling upon engagement of its lig ands (PD-L1 and/or PD-L2) ( 14, 15). The structure of 
murine PD-1 has been resolved ( 16). PD-1 and fam ily members are  type I transmembrane 
glycoproteins containi ng an Ig Variable–type  (IgV-type) domain responsible for  ligand binding 
and a cytoplasmic tail responsib le for the binding of signaling  molecules. The cytoplasmic tail of 
PD-1 contains 2 tyrosine-base d signaling motifs, an immunorecep tor tyrosine-based inhibition 
motif, and an immunoreceptor tyrosi ne-based switch motif. Follo wing T-cell stimulation, PD-1 
recruits the tyrosine phosphata ses, SHP-1 and SHP-2, to the imm unoreceptor tyrosine-based 
switch motif within its cytoplas mic tail, leading to the dephos phorylation of effector molecules 
such as CD3ζ, PKCθ, and ZAP70, whi ch are involved in the CD3 T- cell signaling cascade (15, 
17-19). The mechanism by which PD- 1 down-modulates T-cell respo nses is similar to, but 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 10 of 66 distinct from, that of CTLA-4, because both molecules regulate an overlapping set of signaling 
proteins (20, 21). PD-1 was show n to be expressed on activated lymphocytes including 
peripheral CD4+ and CD8+ T-cells, B cells, T regs, and natural killer cells (22, 23). Expression 
has also been shown during thymic  development on CD4-CD8- (doub le negative) T-cells, as 
well as subsets of macrophages and dendritic cells (24).  The l igands for PD-1(PD-L1 and PD-
L2) are constitutively expressed or can be induced in a variety  of cell types including 
nonhematopoietic tissues and i n various tumors (11, 21, 25-27).  Both ligands are type 1 
transmembrane receptors contai ning IgV-like and Ig constant–lik e (IgC-like) domains in the 
extracellular region and contain short cytoplasmic regions with  no known signaling motifs. 
Binding of either PD-L1 or PD-L2 t o PD-1 inhibits T-cell activa tion triggered through the T-cell 
receptor. PD-L1 is expressed at low levels on various nonhemato poietic tissues, most notably on 
vascular endothelium; whereas P D-L2 is only detectably expresse d on antigen-presenting cells 
found in lymphoid tissue or chronic  inflammatory environments. PD-L2 is thought to control 
immune T-cell activation in lymphoid organs, whereas PD-L1 serv es to dampen unwarranted T-
cell function in peripheral tis sues (21). Although healthy orga ns express little ( if any) PD-L1, a 
variety of cancers were demonstr ated to express abundant levels  of this T-cell inhibitor. High 
expression of PD-L1 on tumor cells  (and to a lesser extent of P D-L2) has been found to correlate 
with poor prognosis and survival in v arious cancer types, inclu ding renal cell carcinoma (28), 
pancreatic carcinoma (29), hepa tocellular carcin oma (30), and o varian carcinoma (31). 
Furthermore, PD-1 has been suggest ed to regulate tumor-specific  T-cell expansion in subjects 
with melanoma (32).  The observed correlation of cli nical prognosis with PD-L1 expre ssion in multiple cancers 
suggests that the PD-1/PD-L1 pa thway plays a critical role in t umor immune evasion and should 
be considered as an attractive ta rget for therapeutic intervent ion. Therapeutic studies in mouse 
models show that administrati on of antibodies blocking PD-1/PD- L1 interaction enhances 
infiltration of tumor-specific CD 8+ T-cells and le ads ultimatel y to tumor rejection, either as a 
monotherapy or in combination with  other treatment modalities. Anti–mouse PD-1 and anti–
mouse PD-L1 have demonstrated ant itumor responses as a monother apy in models of squamous 
cell carcinoma, pancreatic carci noma, melanoma, and colorectal carcinoma. Blockade of the PD-
1 pathway effectively promoted CD8 + T-cell infiltration into th e tumor and the presence of IFN-
γ, granzyme B, and perforin, indic ating that the mechanism of a ction involved loc al infiltration 
and activation of effector T-c ell function in vivo (29, 33-36).  In addition, the combination of 
gemcitabine and anti–PD-L1 mAb de monstrated synergy in the reje ction of pancreatic mouse 
tumors (29). In-house experiment s have confirmed the in vivo ef ficacy of PD-1 blockade as a 
monotherapy as well as in combi nation with chemotherapy in syng
eneic mouse tumor models. 
1.3.2 Clinical Data in NSCLC 
The PD-1 pathway represents a majo r immune control switch, whic h may be engaged by tumor 
cells to overcome active T-cell immu ne surveillance. Pembrolizu mab (KEYTRUDA ®, MK-
3475; previously known as SCH  900475 and ORG 307488- is a poten t and highly selective 
humanized monoclonal antibody (mAb ) of the immunoglobulin G4(Ig G4)/kappa isotype 
designed to directly block the  interaction between PD-1 and its  ligands, PD-L1 and PD-L2. This 
blockade enhances functional ac tivity of the target lymphocytes  to facilitate tum or regression and 
ultimately immune rejection.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 11 of 66 The clinical activity of Pembrolizumab in NSCLC was demonstrate d in two clinical trials. In the 
initial phase I tria l (KEYNOTE-001), patients with advanced NSC LC were treated with either 
2mg/kg or 10mg/kg every 3 weeks  or 10mg/kg every 2 weeks. The t reatment was well tolerated 
with the most frequent side ef fects including fatigue, pruritus , and decreased appetite. Among all 
patients, the objective respons e rate (ORR) was 19.4% and the m edian duration of response was 
12.5months. Median progression fre e survival (PFS) was 3.7 mont hs and median OS was 12 
months. Among patients with >50%  PD-L1 expression on tumor cell s, the response rate was 
45.2% with a PFS of 6.3 months. Median OS in this group was not  reached (10).  
 In a subsequent phase II/III tria l (KEYNOTE-010) of single-agen t pembrolizumab versus 
docetaxel for PD-L1 positive (>1% PD-L1 staining on tumor cells ) NSCLC, patients were 
randomized 1:1:1 to receive eith er pembrolizumab 2mg/kg, pembro lizumab 10mg/kg, or 
docetaxel 75mg/m
2 intravenously (IV) every 3 w eeks.  In the total population, me dian overall 
survival favored the pembroliz umab arms with 10.4 months in the  2mg/kg arm, 12.7 months in 
the 10mg/kg arm, and 8.5 months i n the docetaxel arm.  PFS was not statistically  improved in the 
pembrolizumab arms when consid ering all patients.  In the group  of patients with >50% PD-L1 
staining, a more substantial bene fit was seen for the pembroliz umab arms with a median OS of 
14.9 months in the 2mg/kg arm ve rsus 8.2 months in the docetaxe l arm (HR 0.54, =0.0002) and 
17.3 months in the 10mg/kg arm ve rsus 8.2 months in the docetax el arm (HR 0.50, p<0.0001).  
PFS was also statistically si gnificantly longer in the pembroli zumab arms for patients with >50% 
PD-L1 staining. Pembrolizumab a ppeared to be muc h better tolera ted than docetaxel with grade 
3-5 treatment-related a dverse events (TRAEs) of 13% and 16% in the 2mg/kg and 10mg/kg 
pembrolizumab respectively versus  35% in the docetaxel arm (9).   Based on the data from these 
trials, pembrolizumab was  FDA-approved for the 2nd line treatment of PD-L1 positive (>50% 
staining on tumor cells) NSCLC a nd is currently under review by  the FDA for the tissue 
polypeptide-specific anti gen (TPS) >1% population. 
1.3.3 Safety Data in Combinati on with Chemotherapy 
The safety of combin ing immunotherapy with c hemotherapy has bee n demonstrated in several 
early phase trials in NSCLC, and l arger trials are currently be ing conducted to assess the efficacy 
of these combinations.  In a phase  I trial (KEYNOTE-021), pembr olizumab was added to 
platinum doublet chemotherapy in p atients with treatment-naïve NSCLC. Subjects were 
randomized to receive either 2m g/kg or 10mg/kg of pembrolizumab  in combination with either 
carboplatin (AUC 6) and  paclitaxel (200mg/m2) or carboplatin (AUC 5) and pemetrexed 
(500mg/m2) IV every 3 weeks for 4 cycl es followed by either pembrolizuma b or pembrolizumab 
and pemetrexed maintenance. The c arboplatin and paclitaxel arm demonstrated 15% grade 3-4 
TRAEs including anemia and rash in one patient each. The carbop latin and pemetrexed arm 
experienced 38% grade 3-4 AEs inc luding reversible transaminase  elevations (n=3), anemia 
(n=2), rash (n=1), and colitis (n= 2). No grade3-4 febrile neutr openia was observed, and there 
were no treatment-related deaths  on either arm. ORR were 30% in  the carboplatin/paclitaxel arm 
and 58% in the carboplatin/pemetrex ed arm at the time of analys is with the majority of patients 
remaining on therapy in both arm s (37). This study suggests tha t the combination of 
pembrolizumab and platinum doublet chemotherapy with a taxane o r pemetrexed has a 
reasonable safety profile, and the refore, it is likely that the  combination of pembrolizumab with 
either single-agent taxane or pemetrexed will be well tolerated  as well. 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 12 of 66 There is no direct safety data  with the combination of pembroli zumab and gemcitabine, however, 
there is a phase I trial of nivol umab (another PD-1 inhibitor) with platinum doublet 
chemotherapy that includes a gemc itabine arm. In this trial, tr eatment-naïve patients were 
randomized to one of 4 treatment r egimens. The first three arms  combined nivolumab 10mg/kg 
IV every three weeks wit h either cisplatin (75mg/m2) and gemcitabine (1250mg/m2), cisplatin 
(75mg/m2) and pemetrexed (500mg/m2), or carboplatin (AUC 6)  and paclitaxel (200mg/m2). The 
last arm combine d nivolumab 5mg/m2 with carboplatin (AUC 6)  and paclitaxel (200mg/m2).  All 
regimens were given for 4 cyc les followed by nivolumab maintena nce. No dose-limiting 
toxicities (DLTs) were seen duri ng the first 6 weeks of treatme nt, and there were no reported 
treatment-related deaths. Grade  3-4 AEs were seen in 45% of pat ients (range 25-73% across all 
arms) and most commonly include d pneumonitis (grade 4, n=1; gra de 3, n=3), fatigue (grade 3, 
n=3), and acute renal failure ( grade 3, n=3). Grade 3 select AE s occurred in ≤7% of patients, and 
overall, 20% of patients disconti nued any study medication beca use of treatment-related AEs 
(38). This study shows that the c ombination of nivolumab with p latinum doublet chemotherapy 
including gemcitabine, pemetre xed, and paclitaxel has a managea ble safety profile and reflects 
the additive toxiciti es of immunotherapy a nd chemotherapy. Base d on this, the combination of 
immunotherapy with singl e agent gemcitabine , pemetrexed, or a t axane would be expected to 
have a reasonable safety profile as well. 
1.4 Rationale 
1.4.1 Study Rationale 
While many patients who initi ally respond to immunotherapy have  prolonged durations of 
response, the majority of patients  will still ulti mately progre ss on these therapies. Little is 
currently known about the resistanc e mechanisms responsible for  this progression, and there is 
currently no data to suggest wh ether immunotherapy has any bene fit or should be continued 
following clear progression. Previ ous studies in both NSCLC and  other malignancies have 
shown differing results in the bene fit of continuing targeted a gents. A trial of continuation 
trastuzumab following progressi on in human epidermal growth fac tor receptor 2 (HER-2)-
positive early and advanced breast  cancer shows a significant o verall survival benefit for the 
combination of chemo therapy and trastuzuma b compared with chemo therapy alone (39). 
Furthermore, treatment with be vacizumab, a monoclonal antibody (mAb) target ing vascular 
endothelial growth factor (VEG F) following progression on first  line therapy suggests a 
significant OS advantage for th e patients who were continued on  bevacizumab (40). Lastly, 
androgen deprivation therapy (ADT) is routinely continued beyon d progression in the treatment 
of metastatic prostate cancer ( 41). Conversely, c ontinued treat ment with the TKI erlotinib did not 
show benefit when continued be yond progression in patients with  advanced EGFR-mutated 
NSCLC (42). Therefore, furthe r study of continuation of immunot herapy at the time of 
progression is warranted. 
1.4.2 Dose Selection Rationale 
The dose regimen of 200 mg Q3W of  pembrolizumab is planned for all urothelial ca ncer trials. 
Available PK results in subjec ts with melanoma, NSCLC, and othe r solid tumor types support a 
lack of meaningful dif ference in PK exposur es obtained at a giv en dose among tumor types. An 
open-label Phase 1 trial (PN001)  in melanoma subjects is being conducted to evaluate the safety 
and clinical activity o f single agent pembrolizumab. The dose e scalation portion o f this trial 
evaluated three dose levels , 1 mg/kg, 3 mg/kg, and 10 mg/kg, ad ministered every 2 weeks 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 13 of 66 (Q2W) in subjects with advance d solid tumors. All three dose le vels were well tolerated and no 
DLTs were observed. This first i n human study of pembrolizumab showed evidence of target 
engagement and objective evidence  of tumor size reduction at al l dose levels (1 mg/kg, 3 mg/kg 
and 10 mg/kg Q2W). No maximum tol erated dose (MTD) has been ide ntified. 
 In KEYNOTE-001, two randomized cohor t evaluations of melanoma s ubjects receiving 
pembrolizumab at a dose of 2 m g/kg versus 10 mg/kg Q3W have bee n completed. The clinical 
efficacy and safety data demonstrate a lack of clinically impor tant differences in efficacy 
response or safety profile at th ese doses. For example, in Coho rt B2, advanced melanoma 
subjects who had receiv ed prior ipilimumab therapy were randomi zed to receive pembrolizumab 
at 2 mg/kg versus 10 mg/kg Q3W. T he overall ORR was 26% (21/81)  in the 2mg/kg group and 
26% (25/79) in the 10 mg/kg group (fu ll analysis set (FAS)). Th e proportion of subjects with 
TEAEs, grade 3-5 drug-related AEs , serious drug-related AEs, de ath or discontinuation due to an 
AE was comparable between groups  or lower in the 10 mg/kg group . 
 Available pharmacokinetic (PK) results in subjects with melanom a, NSCLC, and other solid 
tumor types support a lack of m eaningful differe nce in PK expos ures obtained at a given dose 
among tumor types. Population PK analysis has been performed an d has confirmed the 
expectation that intrinsic fact ors do not affect exposure to pe mbrolizumab to a clinically 
meaningful extent. Taken togeth er, these data support the use o f lower doses (with similar 
exposure to 2 mg/kg Q3W) in a ll solid tumor indications. 
 Selection of 200 mg as the appropr iate dose for a switch to fix ed dosing is based on simulation 
results indicating that 200 mg will provide exposures that are reasonably consistent with those 
obtained with 2 mg/kg dose and impor tantly will maintain indivi dual patient exposures within 
the exposure range established i n melanoma as associated with m aximal clinical response. A 
population PK model, which char acterized the influence of body weight and other patient 
covariates on exposure, has bee n developed using a vailable data  from 476 subjects from PN001. 
The distribution of exposures from the 200 mg fixed dose are pr edicted to considerably overlap 
those obtained with the 2 mg/kg dos e, with some tendency for in dividual values to range slightly 
higher with the 200 mg fixed dose. T he slight increase in PK va riability predicted for the fixed 
dose relative to weight-base d dosing is not expected to be clin ically important given that the 
range of individual exposures is w ell contained within the rang e of exposures shown in the 
melanoma studies of 2 and 10 mg/kg  to provide similar efficacy and safety. The population PK 
evaluation revealed that there wa s no significant impact of tum or burden on exposure. In 
addition, exposure was similar be tween the NSCLC and melanoma i ndications. The refore, there 
are no anticipated changes in expos ure between different tumor 
types and indication settings. 
1.4.3 Rationale for Historical Control 
Previous studies evaluating si ngle-agent chemotherapy following  progression on a platinum 
doublet have shown consistently tha t the PFS or TTP in these st udies is approximately 3 months.  
In a trial of docetaxel versus be st supportive car e (BSC), the chemotherapy arm demonstrated a 
TTP of 10.6 weeks (43), and in a tri al of docetaxel versus vino relbine or ifosfamide, the 
docetaxel arm showed a TTP of 8.5 w eeks (44).  A more recent tr ial comparing single-agent 
docetaxel versus pemetrexed in t he second-line setting demonstr ated a PFS of 2.9 months for 
both arms (45).  Given the consis tent findings in these studies , a PFS of 3 months appears to be 
an appropriate histor ical control arm.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 14 of 66  
2. STUDY OBJECTIVES AND ENDPOINTS 
2.1 Objectives 
2.1.1 Primary Objective 
 To assess whether continuation o f pembrolizumab in combination with next-line 
chemotherapy (either gemcitabine , docetaxel, or pemetrexed [non -squamous only]) will 
prolong PFS by RECIST 1.1 criteria in patients who previously b enefitted from a PD-1/ 
PD-L1 inhibitor (PFS ≥ 3 months) but now have progressive disea se as compared to 
historical controls 
2.1.2 Secondary Objectives 
 To estimate PFS by immune-rela ted RECIST (irRECIST) 
 To estimate ORR by RECIST  1.1 and irRECIST criteria  
 To estimate clinical benefit rate as defined by RECIST 1.1 and irRECIST 
 To estimate OS 
 Assess the toxicity of pembroli zumab in combination with next-l ine chemotherapy 
(gemcitabine, docetaxel, or pe metrexed [non-squamous only]) 
2.1.3 Correlative/Exploratory Objectives 
 To assess tumor PD-L1 status at ba seline (prior to initial trea tment with PD-1 inhibitor), 
at time of progression on PD-1 or P D-L1 inhibitor (study entry) , and at time of 
progression on combination of pemb rolizumab and chemotherapy (s afety follow up 
visit) 
 To correlate ORR, PFS, and clinical  benefit rate with the resul ts of proteomic analysis 
and lipidomic profiling 
 To correlate ORR, PFS, and clinical  benefit rate with the resul ts of NeoTYPE Lung 
Tumor Profile Genetic Analysis 
2.2 Endpoints 
2.2.1 Primary Endpoint 
 PFS as measured by RECIST 1.1 criteria 
2.2.2 Secondary Endpoints 
 PFS as measured by irRECIST criteria 
 Objective response rate (CR+ PR) assessed via RECIST 1.1 and irR ECIST 
 Clinical benefit rate - defined a s any subject with stable dise ase (SD) for ≥ 3 months, 
partial response (PR), or compl ete response (CR) assessed via R ECISIT 1.1 and 
irRECIST  
 OS  
 Toxicity will be graded according to the National Cancer Instit ute’s Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.   
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 15 of 66 3. ELIGIBILITY CRITERIA 
3.1 Inclusion Criteria 
Subjects must meet all of the f ollowing applicable inclusion cr iteria to participat e in this study: 
1. Written informed cons ent and HIPAA authoriz ation for release of  protected health 
information NOTE:  HIPAA authorization may be incl uded in the informed consent or  obtained 
separately. 
 
2. Age ≥ 18 years at the time of consent 
 
3. Histological or cytological evid ence of stage IV NSCLC (any his tology) 
 
4. Subjects must have pr ogressed on or after pr evious platinum-bas ed chemotherapy. 
Chemotherapy may have previously  been given with a PD-1 or PD-L 1 inhibitor. Subjects 
must have also progressed on or a fter receiving any PD-1 or PD- L1 inhibitor (including 
pembrolizumab) as their most re cent therapy and m ust have had a t least a 3-month PFS 
on this therapy. 
 
5. Subjects must be enrolled on the  trial within 12 weeks of their  last infusion of PD-1 or 
PD-L1 inhibitor therapy. 
 
6. Subjects whose tumors harbor  a mutation in EGFR exon 19 or 21 o r have gene 
rearrangements in ALK or ROS1 mus t have already been treated wi th standard targeted 
therapies. NOTE: Subjects mu st also have progressed on or after  platinum-containing 
combination chemotherapy. 
 
7. ECOG Performance Status of 0 or  1 within 28 days prior to regis tration for protocol 
therapy. 
 
8. Must be fit enough to receive next-l ine chemotherapy (either ge mcitabine, docetaxel, or 
pemetrexed [non-squamous only]) a ccording to the discretion of the treating physician. 
 
9. Adequate laboratory values obtai ned within 28 days prior to reg istration for protocol 
therapy (as defined in table 1 below).  
 
Table 1 Adequate Organ F unction Laboratory Values 
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 K/mm3 
Platelets  ≥100,000 K/mm3 
Hemoglobin without transfusion or EPO 
dependenc y (within 7 da ys of assessment)  ≥9 g/dL or ≥5.6 mmol/L  
Renal   
Serum creatinine OR 
Measured or calculateda creatinine 
clearance 
(GFR can also be used in place of creatinine or CrCl)
 ≤1.5 X upper limit of normal (ULN) OR 
 
≥60 mL/min for subject with creatinine 
levels > 1.5 X institutional ULN  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 16 of 66 Hepatic   
Serum total bilirubi n ≤ 1.5 X ULN OR 
 Direct bilirubin ≤ ULN for subjects with 
total bilirubin levels > 1.5 ULN  
AST (SGOT) and ALT (SGPT)  ≤ 2.5 X ULN  
Coagulation  
International Normal ized Ratio (INR) or 
Prothrombin Time (PT); Activated Partial 
Thromboplastin Time (aPTT)  ≤1.5 X ULN unless subject is receiving 
anticoagulant therapy. In the case of anticoagulants, PT/INR/PTT must be within therapeutic ra nge of intended use of 
anticoa
gulants  
aCreatinine clearance should be calculated per institutional sta ndard.  
 
10. Women of childbearing potential  (WOCBP) must have a negative ur ine or serum 
pregnancy test within 7 days pr ior to study registration and/or  within 72 hours of first 
dose of study drugs. If the urine test is positive or cannot be  confirmed as negative, a 
serum pregnancy test will be required. Female subjects will be consider ed of childbearing potential un less they are either:  
(1) postmenopausal--defined as at  least 12 months with no menses wi thout an alternative 
medical cause; in women < 45 years  of age a high follicle stimu lating hormone (FSH) 
level in the postmenopausal ra nge may be used to confirm a post -menopausal state in 
women not using hormonal contrace ption or hormonal replacement therapy. In the 
absence of 12 months of amenorrh ea, a single FSH measurement is  insufficient. OR 
(2) have had a hysterectomy and/or  bilateral oophore ctomy, bilatera l salpingectomy or 
bilateral tubal ligation/occlus ion at least 6 weeks prior to sc reening. OR 
(3) have a congenital or acquired cond ition that prevents childbear ing. 
 
11. Women of childbearing potential m ust be willing to use two meth ods of contraception 
(see section 5.5.2) or abs tain from heterose xual activity from the point of registration 
through 120 days after the l ast dose of study drug.  
 
12. Male subjects capable of fatheri ng a child must agree to use an  adequate method of 
contraception (see section 5.5.2)  starting with the first dose of the study drug through 120 
days after the last  dose of the study drug. 
Male subjects will be considered to be capable of fathering a c hild unless they have 
azoospermia (whether due to ha ving had a vasectomy or due to an  underlying medical 
condition). 
3.2 Exclusion Criteria 
Subjects meeting any of the criteria below may not participate in the study: 
	
1. Pregnant or breastfeeding, or expe cting to conceive or father c hildren within the 
projected duration of the trial, s tarting with the pre-screenin g or screening visit through 
120 days after the last do se of trial treatment. 
 
2. Active central nervous syste m (CNS) metastases.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 17 of 66 NOTE: Subjects who are symptoma tic and have not undergone prior  brain imaging must 
undergo a head computed t omography (CT) scan or brain MRI withi n 28 days prior to 
registration to exclude  brain metastases.  
NOTE: A subject with prior brain m etastasis may be considered i f they have completed 
their treatment for brain metas tasis at least 4 weeks prior to study registration, have been 
off corticosteroids for ≥ 2 week s, are asympto matic, and there is no evidence of 
progression on brain ima ging (CT or MRI). 
 
3. Treatment with any investigationa l agent withi n 28 days prior t o registration for protocol 
therapy with the exception of P D-1 or PD-L1 inhibitors.  
 
4. No active second cancers with t he exception of localized non-me lanoma skin cancer, in-
situ cervical or in-s itu bladder cancer. 
 
5. Evidence of active autoimmune disease requiring systemic treatm ent within the past 90 
days or a documented history of c linically severe autoimmune di sease, or a syndrome that 
requires systemic steroids or  immunosuppressive agents.  
NOTES: Subjects with v itiligo or resolved c hildhood asthma/atop y would be an 
exception to this rule. Subjects that require intermittent use of bronchodilators or local 
steroid injections would not be  excluded from the study. Subjec ts with hypothyroidism 
stable on hormone replacement or S jögren’s syndrome will not be  excluded. 
 
6. Prior solid organ or s tem cell transplant. 
 
7. History of interstitial lung dis ease or pneumonitis related to the use of immunotherapeutic 
drugs. Subjects with a history of pn eumonitis which is unrelate d to the use of 
immunotherapeutic drugs may partic ipate at the discretion of th e treating physician. 
 
8. History of an immune-related toxi city requiring treatment with corticosteroids during 
prior PD-1/ PD-L1 inhibitor treatment. 
 
9. Diagnosis of immunodeficiency or i s receiving chronic systemic corticosteroi d therapy or 
other immunosuppressive therapy (excludes inhaled corticosteroi ds) within 7 days of 
study registration 
 
10. History of psychiatric illness or  social situati ons that would limit compliance with study 
requirements 
 
11. Clinically active in fection (≥ Grade 2) as judged by the site i nvestigator.  
 
12. Known history of human immunodefic iency virus (HIV) infection o r chronic hepatitis B 
or C. NOTE: HIV, HBV or HCV  testing is not required. 
 
13. History or current evidence  of any condition, therapy, or labor atory abnormality that 
might confound the results of the  trial, interfere with the sub ject’s participation for the 
full duration of the trial, or i s not in the best  interest of t he subject to participate, in the 
opinion of the site investigator. 
 
14. Known history of active TB (Bacillus Tuberculosis). 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 18 of 66 15. History of hypersensitivity t o pembrolizumab, docetaxel, gemcit abine, pemetrexed or any 
of their excipients. 
 
16. Has received a live vaccine w ithin 30 days prior to planned sta rt of study therapy. 
Note:  Seasonal influenza vaccines for injection are generally inactivated flu vaccines and 
are allowed; however intranasal influenza vaccines (e.g., Flu-M ist®) are live attenuated 
vaccines, and are not allowed. 
 
4. SUBJECT REGISTRATION 
All subjects must be registered through Big Ten CRC Administrat ive Headquarters’ (AHQ) 
electronic data capture (EDC) s ystem OnCore. A subject is consi dered registered when an ‘On 
Study’ date is entered into OnCore.  
5. TREATMENT PLAN 
This is a single-arm phase II study of continuation immunothera py with pembrolizumab 
following initial benefi t with a PD-1 or PD- L1 inhibitor.  Pati ents who have been treated with a 
PD-1 or PD-L1 inhibitor and expe rienced a PFS of ≥3 months will  be enrolled within 12 weeks 
of last dose of PD-1 or PD-L1 i nhibitor.  On Day 1 of each 3-we ek cycle, subjects will first 
receive pembrolizumab at a dose of 200mg IV every three weeks i n combination with 
chemotherapy. Partner chemotherap y will be either gemcitabine 1 000mg/m
2 IV D1 and D8 every 
three weeks, docetaxel 60-75mg/m2 IV D1 every three week s, or pemetrexed 500mg/m2 IV D1 
every 3 weeks (pemetrexed for  non-squamous histologies only).  Subjects will continue to 
receive this combination until progression or intolerable toxic ity.  
5.1 Pre-medication and Hydration 
Premedication and hydration will be  administered as per institu tional standards based on the 
partner chemotherapy selected (ge mcitabine, docetaxel, or pemet rexed).  Pembrolizumab does 
not require any premedication.  
5.2 Chemotherapy + Pembrolizumab Administration 
Partner chemotherapy will be adm inistered as per institutional standards at the doses outlined 
below in Table 2.    
  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 19 of 66 Table 2  Drug Administration  
Drug Administration
Sequence Dose1 Route Schedule2 Cycle 
Length 
Pembrolizumab 1st 200mg Intravenously Day 1 21 days
   
Gemcitabine 
2nd 1000mg/m2 Intravenously Days 1, 8 
21 daysDocetaxel 60-75mg/m2Intravenously Day 1 
Pemetrexed3 500mg/m2 Intravenously Day 1 
1 Body surface area (BSA) should be recalculated per institution al standards for weight changes. The 
starting dose of docetaxel within this range will be at the disc retion of the treating physician. 
2 A window of ±3 days may be a pplied to all study visits to acco mmodate observed holidays, 
inclement weather, scheduling conflicts etc. Date and time of e ach drug administration should be 
clearly documented in subject’s chart and electronic case repor t forms (eCRFs).  
3 Cyanocobalamin (vitamin B 12) should be given at a dose of 1000mcg intramuscularly every 3 cycles 
(9 weeks), and folic acid should be given at a dose of 1mg PO d aily while on pemetrexed. 
5.2.1 Pembrolizumab Administration 
Pembrolizumab 200 mg will be administered as a 30 minute IV inf usion every 3 weeks.  Sites 
should make every effort to targe t infusion timing to be as clo se to 30 minutes as possible.  
However, given the variability of  infusion pumps from site to s ite, a window of -5 minutes and 
+10 minutes is permitted (i.e., infusion time is 30 minutes: -5  min/+10 min). 
 The Pharmacy Manual contains spe cific instructions for the prep aration of the pembrolizumab 
infusion fluid and administrat ion of infusion solution. 
5.3 Concomitant Medications 
Medications or vaccinations speci fically prohibited in the excl usion criteria are not allowed 
during the ongoing trial.  If ther e is a clinical  indication fo r one of these or other medications or 
vaccinations specifically prohi bited during the trial, disconti nuation from trial therapy or 
vaccination may be required.  The  site investigator should disc uss any questions regarding this 
with the Big Ten CRC project ma nager who will communicate with the sponsor-investigator and 
Merck Clinical team regarding th e situation.  The final decisio n on any supportive therapy or 
vaccination rests with the site investigator and/or the subject 's primary physician. There are no 
prohibited therapies during the P ost-Treatment Follow-up Phase.  
5.3.1 Docetaxel Subjects 
Docetaxel is a CYP3A4 substrate . In vitro studies have shown th at the metabolism of docetaxel 
may be modified by the concomitan t administration of compounds that induce, inhibit, or are 
metabolized by cytochrome P450 3A4.  In vivo studies showed that the exposure of docetaxel increased  2.2-fold when it was co-
administered with ketoc onazole, a potent inhibitor of CYP3A4. P rotease inhibitors, particularly 
ritonavir, may increase the e xposure of docetaxel. Concomitant use of docetaxel and drugs that 
inhibit CYP3A4 may increase exposure to docetaxel and should be  avoided. In patients receiving 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 20 of 66 treatment with docetaxel, close monitoring for toxicity and a d ocetaxel dose reduction could be 
considered if systemic adminis tration of a potent CYP3A4 inhibi tor cannot be avoided. 
5.3.2 Pemetrexed subjects 
Although ibuprofen (400 mg four tim es a day) can decrease the c learance of pemetrexed, it can 
be administered with pemetrexed i n patients with normal renal f unction (creatin ine clearance 
≥80 mL/min). No dose adjustment of  pemetrexed is needed with co ncomitant NSAIDs in 
patients with normal renal function.  
Caution should be used when admin istering NSAIDs concurrently w ith pemetrexed to patients 
with mild to moderate renal ins ufficiency (creatinine clearance  from 45 to 79 mL/min). NSAIDs 
with short elimination half-lives (e.g., diclofenac, indomethac in) should be avoided for a period 
of 2 days before, the day of, and 2 da ys following administrati on of pemetrexed. 
 In the absence of data regardi ng potential inte raction between pemetrexed and NSAIDs with 
longer half-lives (e.g., meloxica m, nabumetone), patients takin g these NSAIDs should interrupt 
dosing for at least 5 days befo re, the day of, and 2 days follo wing pemetrexed administration. If 
concomitant administration of N SAIDs is necessary, patients sho uld be monitored closely for 
toxicity, especially myelosuppres sion, renal, and  gastrointesti nal toxicity. 
5.3.3 Allowed Concomitant Medications 
All treatments that the site investigator considers necessary f or a subject’s welfare may be 
administered at the discretion of  the site investigator in keep ing with the community standards of 
medical care. All concomitant me dication will be recorded on th e eCRF including all 
prescription, over-the-counter ( OTC), herbal supplements, and I V medications and fluids. If 
changes occur during the tria l period, documen tation of drug do sage, frequency, route, and date 
may also be included on the CRF.  All concomitant medications rec eived within 28 days before the first dose of tri al treatment and 
30 days after the last  dose of trial treatme nt should be record ed. Concomitant medications 
administered more than  30 days after the las t dose of trial tre atment should be recorded for 
serious adverse events (SAE) and e vents of clinical interest (E CI) as defined in Section 11.2.4. 
5.3.4 Prohibited Concomitant Medications 
Subjects are prohibited from rece iving the following therapies during the Screening and 
throughout the Treatment P hase of this trial: 
 Immunotherapy not specifi ed in this protocol 
 Chemotherapy not specifi ed in this protocol 
 Investigational agents ot her than pembrolizumab  
 Radiation therapy- palliative radiation can be permitted per gu idelines in section 5.3.5   
 Live vaccines within 30 days prio r to the first dose of trial t reatment and while 
participating in the trial. Exam ples of live vaccines include, but are not limited to, the 
following: measles, mumps, rube lla, varicella/zoster, chicken p ox, yellow fever, rabies, 
BCG, and typhoid (oral) vaccine. Seas onal influenza vaccines fo r injection are generally 
killed virus vaccines and are allo wed; however intranasal influ enza vaccines (e.g. Flu-
Mist®) are live attenuated vaccines, and are not allowed. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 21 of 66  Systemic glucocorticoids for a ny purpose other than to modulate  symptoms from an ECI 
(see section 11.2.4) of suspected  immunologic et iology or for u se as anti-emetic 
prophylaxis per standard chemot herapy protocols. The use of phy siologic doses of 
corticosteroids may be approved a fter consultation with the Big  Ten CRC project 
manager and the spons or-investigator.  
 
Subjects who, in the assessment  by the site investigator, requi re the use of any of the 
aforementioned treatments for cl inical management should be rem oved from the trial. The 
Exclusion Criteria describes ot her medications which are prohib ited in this trial. 
5.3.5 Concomitant Palliative Radiotherapy 
The potential for overlapping toxi cities with radiotherapy and pembrolizumab cur rently is not 
known. Therefore, palliative radi otherapy is not recommended wh ile receiving pembrolizumab. 
If palliative radiotherapy is re quired, pembrolizumab should be  withheld for at least 1 week 
before, during, and 1 week after r adiation. Subjects should be closely monitored for any potential 
toxicity during and after receiv ing radiotherapy, and AEs shoul d resolve to Grade ≤ 1 prior to 
resuming pembrolizumab.  
 Non-target bone lesions without l ung tissue included in the pla nned radiation field may 
receive palliative radiotherapy.  
 Patients would also be permitte d to continue on trial if they u ndergo palliative radiation 
to brain metastases if 1) this i s their only site of progressiv e disease (no non-CNS 
progression) and 2) their treati ng physician feels  restarting t rial therapy is sa fe and in the 
best interest of the patient.   
Details of palliative radiothe rapy should be documented in the source records and eCRF. Details 
in the source records should inc lude: dates of treatment, anato mical site, dose administered and 
fractionation schedule, and advers e events. If warranted, sympt oms requiring palliative 
radiotherapy should be evaluate d for objective evidence of dise ase progression. 
5.4 Supportive Care 
Subjects should receive appropr iate supportive ca re measures as  deemed necessary by the site 
investigator. Suggested supportive care measures for the manage ment of AEs with potential 
immunologic etiology are outlined b elow. Where appropriate, the se guidelines include the use of 
oral or intravenous treatment wit h corticosteroids as well as a dditional anti-inflammatory agents 
(please see section 5.3.2 for gui delines on concomit ant adminis tration of NSAIDS and 
pemetrexed) if symptoms do not imp rove with admin istration of c orticosteroids.   Note that 
several courses of steroid tap ering may be necessary as symptom s may worsen when the steroid 
dose is decreased. For each disord er, attempts should be made t o rule out other causes such as 
metastatic disease or  bacterial or viral i nfection, which might  require additional supportive care. 
The treatment guidelines are int ended to be applied when the in vestigator determines the events 
to be related to pe mbrolizumab.  
 Note: if after the evaluation t he event is determined not to be  related, the inves tigator does not 
need to follow the treatment gui dance (as outlined below). It m ay be necessary to perform 
conditional procedures such a s bronchoscopy, endoscopy, or skin  photography as part of 
evaluation of the event.   
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 22 of 66 Management of Pembrolizumab Infusion Related Reactions 
Pembrolizumab may cause severe or  life-threatening infusion-rea ctions including severe 
hypersensitivity or anaphylaxis. S igns and symptoms usually dev elop during or shortly after drug 
infusion and generally resolve  completely within 24 hours of co mpletion of infusion. 
 
Table 3  below  shows treatment guidelines for s ubjects who experience an infus ion reaction 
associated with administr ation of pembrolizumab. 
 
Table 3 : Pembrolizumab Infusion React ion Treatment Guidelines 
NCI CTCAE Grade Pembrolizumab  Treatment Premedication at 
subsequent dosing 
Grade 1 
Mild reaction; infusion 
interruption not indicated; 
intervention not indicate d Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically stable in the opinion of the investigator. None 
Grade 2 
Requires infusion interruption 
but responds promptly to 
symptomatic treatment (e.g., 
antihistamines, NSAIDS, narcotics, IV fluids); 
prophylactic medications 
indicated for < =24 hrs Stop Infusion and monitor symptoms. 
Additional appropriate medi cal therapy may include 
but is not limited to: 
IV fluids 
Antihistamines NSAIDS 
Acetaminophen 
Narcotics 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically stable 
in the opinion of the investigator. If symptoms resolve within one hour of stopping 
drug infusion, the infusion may be restarted at 50% 
of the original infusion rate (e.g., from 100 mL/hr to 
50 mL/hr).  Otherwise dosing will be held until 
symptoms resolve and the subject should be premedicated for the next scheduled dose. 
Subjects who develop Grade 2 toxicity despite 
adequate premedication should be permanently 
discontinued from further pembrolizumab 
administration (chemotherapy can continue per 
section 6.2.1)Subject may be 
premedicated 1.5h (± 30 minutes) prior to 
infusion of 
pembrolizumab with:  
Diphenhydramine 50 
mg po (or equivalent dose of antihistamine). 
 
Acetaminophen 500-1000 mg po (or 
equivalent dose of 
antipyretic). 
Grades 3 or 4 
Grade 3: 
Prolonged (i.e., not rapidly 
responsive to symptomatic medication and/or brief 
interruption of infusion); 
recurrence of symptoms following initial improvement; 
hospitalization indicated for 
other clinical sequelae (e.g., renal impairment, pulmonary infiltrates) 
Grade 4: 
Life-threatening; pressor or 
ventilator
y support indicate d Stop Infusion. 
Additional appropriate medi cal therapy may include 
but is not limited to: 
IV fluids Antihistamines 
NSAIDS 
Acetaminophen Narcotics 
Oxygen 
Pressors Corticosteroids 
Epinephrine** 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically stable 
in the opinion of the investigator. Hospitalization may be indicated. No subsequent dosing 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 23 of 66 NCI CTCAE Grade Pembrolizumab  Treatment Premedication at 
subsequent dosing 
**In cases of anaphylaxis, epinephrine should be 
used immediately. Subject is permanently discontinued from further 
pembrolizumab (chemotherapy can continue per 
section 6.2.1).
Appropriate resuscitation equipment should be available and a p hysician readily available during the period of drug 
administration. 
5.4.1 Supportive Care Guidelines for Pneumonitis 
Subjects with symptomatic pneumonitis should immediately stop r eceiving pembrolizumab and 
have an evaluation. The evalua tion may include bronchoscopy and  pulmonary function tests to 
rule out other causes such as in fection. If the subject is dete rmined to have study drug associated 
pneumonitis, the suggested treatme nt plan is detailed in Table 4. 
 For Grade 2 pneumonitis that imp roves to ≤ Grade 1 within 12 we eks, the following rules should 
apply: 
 First episode of pneumonitis 
o May increase dosing interval by one  week in subsequent cycles ( permanent change) 
 Second episode of pneumonitis – perm anently discontinue pembrol izumab if upon 
rechallenge subject develops pneumonitis 
 Grade 2 
o Partner chemotherapy may cont inue per physician discretion 
5.5 Diet/Activity/Other Considerations 
5.5.1 Diet 
Subjects should maintain a norma l diet unless mo difications are  required to manage an AE such 
as diarrhea, nausea or vomiting. 
5.5.2 Contraception 
Pembrolizumab may have adverse effects on a fetus in utero. Fur thermore, it is not known if 
pembrolizumab has tran sient adverse effect s on the composition of sperm.  
 Non-pregnant, non-breast-feeding w omen of childbearing potentia l (see section 3.1.10) may be 
enrolled if they are willing to us e 2 methods of birth control.  The two methods of birth control 
can be either two barrier methods o r a barrier me thod plus a ho rmonal method to prevent 
pregnancy. Subjects should start  using birth control from the s creening visit, throughout the 
study period, and up to 120 days after  the last dose of study d rug.  
 The following are considered ade quate barrier methods of contra ception: diaphragm, condom (by 
the partner), copper intrauteri ne device, sponge, or spermicide . Appropriate hormonal 
contraceptives will include any registered and marketed contrac eptive agent that contains an 
estrogen and/or a progestational agent (including oral, subcuta neous, intrauterine, or 
intramuscular agents).  Subjects should be informed that taking the study medication ma y involve unknown risks to the 
fetus (unborn baby) if pregnancy w ere to occur during the study . In order to participate in the 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 24 of 66 study they must adhere to the con traception requir ement (descri bed above) for t he duration of the 
study and during the follow-up peri od defined in section 11.2.3 . If there is any question that a 
subject will not reliably comply with the requirements for cont raception, that subject should not 
be entered into the study. 
5.5.3 Use in Pregnancy 
If a subject becomes pregnant w hile on treatment with pembroliz umab, the subject will 
immediately be removed  from all study tre atment and followed up  per protocol. The site 
investigator will make every e ffort to obtain permission to fol low the outcome of the pregnancy 
and report the condition of the f etus or newborn to Big Ten CRC  AHQ who will report to Merck. 
The site will report the outcome of the pregnancy to Big Ten CR C AHQ within 1 working day of 
discovery of event. Big Ten CRC will notify the sponsor-investi gator and Merck within 1 
business day if the outcome i s a SAE (e.g., death, abortion, co ngenital anomaly, or other 
disabling or life-thre atening complication to the mother or new born). See also Section 11.2.3 .  
 
If a male subject impregnates h is female partner the study pers onnel at the site must be informed 
immediately and the pregnancy repor ted to Big Ten CRC AHQ who w ill report the event to 
Merck and followed as descri bed above and in Section  11.2.3. 
5.5.4 Use in Nursing Women 
It is unknown whether pembrolizumab is excreted in human milk. Since many drugs are excreted 
in human milk, and because of the p otential for serious adverse  reactions in the nursing infant, 
subjects who are breast-feeding ar e not eligible for enrollment . 
6. TOXICITIES AND DOSE DELAYS/DOSE MODIFICATIONS 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v4 will be used to grade 
adverse events.  Subjects enrolled in t his study will be evalua ted clinically an d with standard laboratory tests 
before and at regular intervals  during their par ticipation in t his study as specified in Study 
Calendar & Evaluations.  Subjects will be evaluated for A Es (all grades), SAEs, and AEs requiring study drug interruption 
or discontinuation as specified i n Study Calendar & Evaluations .   
6.1 Dose Delays/Dose Modifications 
6.1.1 Subject Withdrawal/Discontinuation Criteria 
Subjects may withdraw consent at  any time for any reason or be withdrawn from the trial at the 
discretion of the site investig ator should any untoward effect occur. In addition, a subject may be 
withdrawn by the spons or-investigator or Big Ten CRC AHQ if enr ollment into the trial is 
inappropriate, the trial plan is  violated, or for administrativ e and/or other safet y reasons. Specific 
details regarding discontinuati on or withdrawal are provided be low.  
 
A subject must be discontinued fro m the trial treatment for any  of the following reasons: 
 Confirmed radiographic diseas e progression by RECIST 1.1 criter ia 
 Unacceptable AEs as described in Section 6.2.1 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 25 of 66  Intercurrent illness that prevents further administration of tr eatment 
 Site investigator’s deci sion to withdraw the subject 
 The subject has a confirmed pos itive serum pregnancy test 
 Noncompliance with trial treat ment or procedure requirements 
 Subject refuses further treatment 
 
A subject must be discontinued fro m the trial (no follow up) fo r any of the following reasons: 
 The subject or legal representa tive (such as a parent or legal guardian) withdraws 
consent. 
 The subject is lost to follow-up 
 
After the end of treatment, each s ubject will be followed for 3 0 days for AE monitoring (SAEs 
will be collected for 90 days afte r the end of treatment as des cribed in Sections 11.2.4 and 
11.2.5). Subjects who discontinue for  reasons other than progre ssive disease will have post-
treatment follow-up for disease status until disease progressio n, initiating a non-study cancer 
treatment, withdrawing consent, or  becoming lost to follow-up. After documented disease 
progression each subject will be fol lowed for overall survival until death, withdrawal of consent, 
or the end of the study, whichever  occurs first. See also Secti on 7.4. 
 When a subject discontinues/withdr aws prior to trial completion , all applicable activities 
scheduled for the final trial vi sit should be pe rformed at the time of disconti nuation. Any AEs 
which are present at the time o f discontinuation/withdrawal sho uld be followed in accordance 
with the safety requireme nts outlined in Section 11.2.1.  
6.1.2 Treatment Delay 
If either Day 1 pembrolizumab or D ay 1 of the partner chemother apy agent is delayed, all study 
drugs must be delayed until treatment can resume.  If the toxic ity is clearly attributable to one 
agent, the other agent can be res umed alone at a normal dose an d schedule after one week.  If the 
toxicity resolves, the combina tion should be resumed at the nex t scheduled dosing interval (the 
drugs should not be on diffe ring schedules).  If it is unclear which drug is causing the toxicity, all 
drugs must be delayed until the toxicity resolves to meet treat ment parameters. 
 Delays of greater than 6 weeks seco ndary to toxicity from chemo therapy agents should 
result in permanent disconti nuation of chemotherapy  
 Delays of greater than 12 weeks se condary to toxi city from pemb rolizumab should result 
in permanent discontinuation of pembrolizumab 
 In either case, treatment with t he other agent may continue at the discretion of the treating 
physician as long as the patient mee ts criteria for continued t herapy 
 
If D8 gemcitabine requires a de lay, this dose can be omitted or  alternatively given on D15 per 
the treating physician’s discre tion.  Delays for D8 gemcitabine  should not prolong a cycle and 
cycles should continue every 21 da ys if subjects meet criteria for continued therapy. 
6.2 Dose Modifications 
6.2.1 Pembrolizumab 
The dose of pembrolizum ab will not be modified.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 26 of 66  
Adverse events (both non-serious a nd serious) associated with p embrolizumab exposure may 
represent an immunol ogic etiology.  These im mune-related AEs (i rAEs) may occur shortly after 
the first dose or several months  after the last dose of pembrol izumab treatment and may affect 
more than on body system simultane ously. Therefore, early recog nition and initiation of 
treatment is critical  to reduce complica tions. Based on existin g clinical study data, most irAEs 
were reversible and could be man aged with interruptions of pemb rolizumab, administration of 
corticosteroids and/or other s upportive care. For suspected irA Es, ensure adequate evaluation to 
confirm etiology or exclude othe r causes. Additi onal procedures  or tests such as bronchoscopy, 
endoscopy, skin biopsy may be incl uded as part of the evaluatio n. Based on the severity of 
irAEs, withhold or permanently d iscontinue pemb rolizumab and ad minister corticosteroids. Dose 
modification and toxicity managem ent guidelines for irAEs assoc iated with pembrolizumab are 
provided in Table 4 below. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-LUN15-029  
07NOV2019 Confidential Page 27 of 66 Table 4: Dose modification and to xicity management guidelines f or immune-related adverse events associated with 
pembrolizumab 
General instructions: 
1. Corticosteroid taper should be initiated upon AE improving to G rade 1 or less and continue to taper over at least 4 weeks. 
2. For situations where pembrolizumab has been withheld, pembroliz umab can be resumed after AE has  been reduced to Grade 1 or 0 a nd corticosteroid has 
been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 weeks of last dose or corticos teroids cannot be reduced 
to ≤10 mg prednisone or equivalent per day within 12 weeks.  
3. For severe and life-threatening irAEs, IV corticosteroid should  be initiated first followed by o ral steroid. Other immunosuppr essive treatment should be 
initiated if irAEs cannot be c ontrolled by corticosteroids.  
Immune-related AEs Toxicity grade or 
conditions 
(CTCAEv4.0) Action taken to 
pembrolizumab irAE management with 
corticosteroid and/or other 
therapies Monitor and follow-up 
Pneumonitis  Grade 2 Withhold   Administer corticosteroids (initial 
dose of 1-2 mg/kg prednisone or equivalent) followed by taper  Monitor participants for signs and 
symptoms of pneumonitis 
 Evaluate participants with suspected 
pneumonitis with radiographic imaging and initiate corticosteroid 
treatment 
 Add prophylactic antibiotics for 
opportunistic infectionsGrade 3 or 4, or 
recurrent Grade 2 Permanently discontinue 
Diarrhea / Colitis  Grade 2 or 3 Withhold  Administer corticosteroids (initial 
dose of 1-2 mg/kg prednisone or 
equivalent) followed by taper  Monitor participants for signs and 
symptoms of enterocolitis (ie, 
diarrhea, abdominal pain, blood or mucus in stool with or without fever) 
and of bowel perforation 
(ie, peritoneal signs and ileus). 
 Participants with ≥ Grade 2 diarrhea 
suspecting colitis should consider GI consultation and performing 
endoscopy to rule out colitis.  
 Participants with diarrhea/colitis 
should be advised to drink liberal 
quantities of clear fluids.  If 
sufficient oral fluid intake is not feasible, fluid and electrolytes should 
be substituted via IV infusion.Grade 4 Permanently discontinue 
AST / ALT elevation or 
Increased bilirubin Grade 2 Withhold  Administer corticosteroids (initial 
dose of 0.5- 1 mg/kg prednisone or equivalent) followed b
y tape r Monitor with liver function tests 
(consider weekly or more frequently 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-LUN15-029  
07NOV2019 Confidential Page 28 of 66 Grade 3 or 4  Permanently discontinue  Administer corticosteroids (initial 
dose of 1-2 mg/kg prednisone or equivalent) followed b
y tape runtil liver enzyme value returned to baseline or is stable 
Type 1 diabetes mellitus (T1DM) or 
Hyperglycemia Newly onset T1DM or  
Grade 3 or 4 
hyperglycemia 
associated with evidence 
of -cell failure Withhold  Initiate insulin replacement 
therapy for participants with 
T1DM  
 Administer anti-hyperglycemic in 
participants with h yperglycemia  Monitor participants for 
hyperglycemia or other signs and 
symptoms of diabetes. 
Hypophysitis Grade 2 Withhold  Administer corticosteroids and 
initiate hormonal replacements as 
clinically indicated.    Monitor for signs and symptoms of 
hypophysitis (including 
hypopituitarism and adrenal insufficiency)  Grade 3 or 4  Withhold or permanently 
discontinue1  
Hyperthyroidism Grade 2 Continue   Treat with non-selective beta-
blockers (eg, propranolol) or 
thionamides as appropriate   Monitor for signs and symptoms of 
thyroid disorders.  
Grade 3 or 4  Withhold or permanently 
discontinue1 
Hypothyroidism Grade 2-4 Continue   Initiate thyroid replacement 
hormones (eg, levothyroxine or 
liothyroinine) per standard of care Monitor for signs and symptoms of 
thyroid disorders.  
Nephritis and Renal 
dysfunction Grade 2 Withhold   Administer corticosteroids 
(prednisone 1-2 mg/kg or 
equivalent) followed by taper.  Monitor changes of renal function 
Grade 3 or 4  Permanently discontinue 
Myocarditis Grade 1 or 2  Withhold  Based on severity of AE 
administer corticosteroids  Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes Grade 3 or 4 Permanently discontinue 
All other immune-related AEs Intolerable/ persistent 
Grade 2 Withhold 
 Based on type and severity of AE 
administer corticosteroids   Ensure adequate evaluation to 
confirm etiology and/or exclude other causes 
Grade 3 Withhold or discontinue 
based on the type of event.  Events that 
require discontinuation 
include and not limited to:  Gullain-Barre 
S
yndrome, encephalitis
Grade 4 or recurrent 
Grade 3  Permanently discontinue 
1. Withhold or permanently discontinue pembrolizumab is at the dis cretion of the investigator or treating physician.   
NOTE: For participants with Grade 3 o r 4 immune-related endocrinopath y where withhold of pembrolizumab is required, pembrolizumab ma y be resumed 
when AE resolves to ≤ Grade 2 and is controlled with hormonal r eplacement therap y or achieved metabolic con trol (in case of T1DM).  
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 29 of 66  
If toxicity does not resolve to G rade 0-1 within 12 weeks after  last infusio n, pembrolizumab 
should be discontinued after consul tation with the Big Ten CRC project manager and the 
sponsor-investigator. With site investigator and sponsor-invest igator agreement, subjects with a 
laboratory AE still at Grade 2 aft er 12 weeks may continue trea tment in the trial only if 
asymptomatic and controlled. If a subject has more than 3 delay s in pembrolizumab dosing due 
to other toxicities specific to this medication, they will be d iscontinued from  pembrolizumab. 
 Subjects who experience a recurrenc e of the same severe or life -threatening event at the same 
grade or greater with re-chal lenge of pembrolizumab should be d iscontinued from 
pembrolizumab.   Subjects who permanently discon tinue pembrolizumab due to toxic ity but who have not 
progressed may remain on single- agent chemotherapy per physicia n discretion until progression 
or intolerable toxicity. 
6.2.2 Partner Chemotherapy  
6.2.2.1  Gemcitabine 
 Gemcitabine should be given a t an initial dose of 1000mg/m
2 IV day 1 and 8 every 3 
weeks.  
 Dose delays of >6 weeks will re sult in permanent discontinuatio n of gemcitabine. 
 Subjects who permanently discontin ue gemcitabine due to toxicit y but who have not 
progressed may remain on single- agent pembrolizumab until progr ession or intolerable 
toxicity. 
 
Dose Level Dose Modification 
Full dose gemcitabine 1000 mg/m2 
75% of full dose 750 mg/m2 
50% of full dose 500 mg/m2 
 
If hematologic toxicity devel ops, dose reductions should be per  drug label guidelines or as 
follows at discretion of site investigator:  
Hematologic Toxicity Gemcitabine dose 
modification 
ANCa ≥1000/mm3 and platelet count ≥100,000/mm3 Administer 100% full dose 
ANCa 500-999/mm3 or platelet count 50,000-99,999/mm3 Administer 75% of full dose 
ANCa <500/mm3 or platelet count <50,000/mm3 Hold dose 
a=absolute neutrophil count 
 Day 1 gemcitabine may resume when ANC is ≥ 1000/mm
3 and platelet count ≥100,000/mm3. 
Day 8 gemcitabine may be given w hen the platelet count is ≥75,0 00/mm3. If platelets are 
<75,000, Day 8 gemcitabine may be  given on Day 15 if the platel et count has improved to 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 30 of 66 ≥75,000/mm3, at the discretion of the trea ting physician. If the platelet count has not improved, 
gemcitabine may be completel y omitted during that cycle. 
 For non-hematologic toxicity, dose reductions should be per dru g label guidelines or as follows 
at discretion of site investigator:  
Non-Hematologic Toxicity Gemcitabine dose 
modification 
Severe (grade 3 or 4) non-hemat ologic toxicity (excludes 
nausea, vomiting, or alopecia- no dose modifications recommended) Hold until resolved and then 
resume at 50% dose 
Unexplained dyspnea (or other evidence of pulmonary toxicity), severe hepatotoxi city, hemolytic uremic syndrome 
(HUS), capillary leak syndrom e (CLS), posterior reversible 
encephalopathy syndrome (PRES) Permanently discontinue 
gemcitabine 
6.2.2.2  Docetaxel 
 Docetaxel should be given at an initial dose of 60-75mg/m2 IV Day 1 every 3 weeks.  If 
dose reduction is required, reco mmend restarting at a 20% reduc tion of full dose every 3 
weeks or per product labeling at the disc retion of the site investigato r.   
 Dose delays of >6 weeks will re sult in permanent discontinuatio n of docetaxel.  
 Subjects who permanently discontinue docetaxel due to toxicity but who have not 
progressed may remain on single-agent pembrolizumab until progr ession or intolerable 
toxicity. 
 
Dose Level Dose Modification 
Full Dose Docetaxel 60-75 mg/m2 
Docetaxel Dose Level –1 20% reduction of full dose 
Docetaxel Dose Level –2 40% reduction of full dose 
Note:  A maximum of two dose redu ctions per subject are allowed . If > 2 dose reductions 
are required, docetaxel will be permanently discontinued.  
 
Docetaxel dose reductions should be per drug label guidelines or as follows, at the discretion of 
the site investigator:  
 Hematologic adjustments: 
Subjects with neutropenic fever  or grade 4 neutropenia lasting > 7 days or grade 4 
thrombocytopenia or thrombocyt openic bleeding should be retreat ed after recovery to 
Grade≤1 or patient baseline wit h a one level dose reduction. 
 
 Peripheral neuropathy adjustments: 
If subject experiences a grade 2 t oxicity, the subsequent retre atment after recovery to ≤ 
Grade 1 should be with a one  level dose reduction. 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 31 of 66 Subjects who have grade 3 or highe r peripheral neuropathy shoul d be permanently 
discontinued from docetaxel.  
 Hypersensitivity react ion adjustments: 
No dose reductions will be made for any hypersensitivity reacti ons. If the subject experiences 
a hypersensitivity reaction, tre atment should be given as indic ated below: 
o Grade 1 symptoms (eg., mild flushing, rash, pruritis)—complete infusion. Supervise at 
bedside. No treatment required. 
o Grade 2 symptoms (e.g., moderate rash, flushing, mild dyspnea, chest discomfort)—
Interrupt infusion. Give intrav enous diphenhydramine 25 mg and intravenous 
dexamethasone 10 mg. Resume infus ion after recovery of symptoms  at a slower rate, 
then increase incrementally to t he initial planned rate. Depend ing on the intensity of the 
reaction observed, additional oral  or IV premedication with an antihistamine should also 
be given for the next c ycle of treatment and t he rate of infusi on should be decreased 
initially and then increased bac k to the planned rate. Report a s an AE. 
o Grade 3 symptoms (e.g., hypotensi on requiring pressor therapy, angioedema, respiratory 
distress requiring bronchodila tion therapy, generalized urticar ia)—Stop infusion. Give 
intravenous diphenhydramine and d examethasone as above. Add epi nephrine or 
bronchodilators if indicated. If wheezing is present, which is not responsive to 
administration of 0.35 cc of nebuliz ed salbutamol solution (or equivalent), epinephrine is 
recommended.  The patient will be  permanently removed from doce taxel. Report as an 
AE. 
o Grade 4 symptoms - Anaphylaxis—P ermanently remove from docetaxe l. Report as an 
AE. 
 
 Hepatic adjustments: 
Patients who develop abnormal liv er function tests for any reas on while on the study will 
have the following docetaxel dose reductions: 
 Abnormal Liver Function Dose Modifications for Docetaxel  
Bilirubin Alkaline 
Phosphatase SGOT (AST) Action 
≥1.5X ULN or > 5 X ULN or > 5 X ULN Wait up to 6 weeks. If 
recovered*, reduce docetaxel 
dose by –1 dose level.  If not, permanently d/c docetaxel.  
< 1.5X ULN and < 5 X ULN and 2.5-5 X ULN Reduce docetaxel dose by –1 
dose level. 
*Bilirubin < 1.5X ULN and alkaline phosphatase < 5 X ULN and SGOT (AST) < 5 X 
ULN. 
ULN= upper limit of normal for institution 
 
 Fluid retention adjustments: 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 32 of 66 If symptomatic, subjects devel oping fluid reten tion may be trea ted with diuretics at the 
investigator’s discretion.   If grade 3, docetaxel should be held until resolution to < grad e 1, then reinstituted after 
recovery, if medically appropria te, with a one level dose reduc tion. 
 Stomatitis adjustments: 
If grade 3 or 4 stomati tis occurs, retreatment after recovery t o grade 1 or less with a one level 
dose reduction. 
 
 Other non-hematologic toxicities: 
If toxicities > 3, docetaxel shoul d be held until resolution to  grade 1 or less, then reinstituted, 
if medically appropriate, after recovery, with a one level dose  reduction. 
 Patients requiring a > 6 wee k delay in docetaxel due to non-hem atologic toxicity will be 
removed from docetaxel treatment. 
6.2.2.3  Pemetrexed 
 Pemetrexed should be given at an initial dose of 500mg/m
2 IV every 3 weeks. 
Pemetrexed should be discontinue d if subjects develop grade 3 o r 4 toxicity after two 
dose reductions or immediately i f grade 3 or 4 neurotoxicity de velops.  
 Dose delays of >6 weeks will re sult in permanent discontinuatio n of pemetrexed. 
 Subjects who permanently discontin ue pemetrexed due to toxicity  but who have not 
progressed may remain on single- agent pembrolizumab until progr ession or intolerable 
toxicity. 
 If a dose reduction for pemetrex ed is required f or hematologic toxicity, reductions should be per 
product labeling or as follows at the discre tion of the investigator: 
 
Hematologic Toxicity Pemet rexed dose modification 
Nadir ANC <500/mm3 and nadir platelets 
≥50,000/mm3 Reduce dose to 75% of previous dose 
Nadir platelets <50,000/mm3 without bleeding 
(regardless of nadir ANC) Reduce dose to 75% of previous dose 
Nadir platelets <50,000/mm3 with bleeding 
(regardless of ANC) Reduce dose to 50% of previous dose 
 
If ≥ grade 3 non-hematologic (exc luding neurotoxicity) toxicity  develops, pemetrexed should be 
withheld until recovery to baseline. Upon recovery, dose reduct ions should be per product label or 
as follows at the discre tion of the investigator: 
 
Non-Hematologic Toxicity Pemetrexed dose modification 
Grade 3 or 4 toxicity (excluding mucositis) Reduce dose to 75% of previous dose 
Grade 3 or 4 diarrhea or  any diarrhea requiring 
hospitalization Reduce dose to 75% of previous dose 
Grade 3 or 4 mucositis Redu ce dose to 50% of previous dose 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 33 of 66 For neurotoxicity:  
 Grade 0-2 Continue at 100% of previous dose 
 Grade 3 or 4 Discontinue treatment 
6.3 Protocol Therapy Discontinuation 
In addition to discontinuation from therapy related to toxiciti es as outlined in section 6.1, a 
subject will also be discontinued from protocol therapy and fol lowed up per protocol under the 
circumstances outlined below. The  reason for discontinuation of  protocol therapy will be 
documented on the eCRF. 
 Documented disease progression per RECIST 1.1. 
 The treating physician thinks a c hange of therapy would be in t he best interest of the 
subject 
 The subject requests to discont inue protocol therapy, whether d ue to unacceptable 
toxicity or for other reasons o If a subject decides to prematur ely discontinue protocol therap y (“refuses treatment”), 
the subject should be asked if he  or she may stil l be contacted  for further scheduled 
study assessments. The outcome  of that discussion should be doc umented in both the 
medical records and in the eCRF. 
 A female subject b ecomes pregnant  
6.4 Protocol Discontinuation 
If a subject decides to withdr aw from the study (and not just f rom protocol therapy) all efforts 
should be made to complete the final study assessments. The sit e study team should contact the 
subject by telephone or through a c linic visit to d etermine the  reason for the study withdrawal. If 
the reason for withdrawal is a n AE, it will be recorded on the eCRF. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-LUN15-029  
07NOV2019 Confidential Page 34 of 66 7. STUDY CALENDAR & EVALUATIONS 
Cycle = 21 daysScreening Cycle 11,2 C y c l e  2 +2 Every other 
cycle2,3Safety follow 
upLong-term 
Follow up5
-28 days Day 
1Day 
8Day 
1 Day 
8Day 1 30 days2,4 
post last doseEvery 3 months 
(±14 days)
REQUIRED  ASSESSMENTS  
Informed Consen t/ HIPAA auth. X  
Medical history including smoking history6X 
Diagnosis and Staging6 X 
Physical exam X X X X
Vital signs, ECOG Performance status7XX X  X
AEs, ECIs & concomitant medications X X X X X
LABORATORY ASSESSMENTS  
Complete Blood Cell Count with diff (CBC) X X1X11X X11X
Comprehensive Metabolic Profile (CMP)8XX1X X
Thyroid Function (TSH, T4, free T3) X  X
PT, INR, aPTT X  
Pregnancy test (serum or urine) WOCBP -7d9-72h9 
DISEASE ASSESSMENT10  
CT of ches t10 X  X10X5
CT or MRI of abdomen and pelvis, if applicable10X X10X5
MRI Brain10 X  
Bone/PET Scan10 X  X10
TREATMENT EXPOSURE  
Pembrolizumab X X 
Partner chemotherapy drug11 X X11X X11
CORRELATIVE STUDIES (SPECIMEN COLLECTION)  
Archival tumor tissue12 X  
Optional tumor biopsy13 X13 X13
Whole Blood samples14 X  
BANKING SAMPLES (SPECIMEN COLLECTION)  
Whole Blood15 X  
Unstained Slides from Tumor Block16 (if available) X  
Serum and Plasma17 X  X
FOLLOW-UP   
Survival status, subsequent therapy   X
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-LUN15-029  
07NOV2019 Confidential Page 35 of 66 Key to Footnotes  
1If screening (baseline) labs were p erformed within 7 days of D1  of treatment, these do not need to be repeated.   
2A window of 3 days will be applie d to all treatment study visit s; for safety follow-up visit and tumor imaging, a 7-day window  will apply. 
3Tumor imaging and thyroid functio n to continue every other cycl e until progression, star ting with cycle 3. 
4A safety follow-up visit will occur 30 days (±7 days) after the  last dose of treatment.  ECIs and SAEs will be collected f or 90 days after the end of 
treatment. See Sections 11.2.4 and 11.2.5. 
5Subjects without documented disease progression will be followe d for every 3 months for 1 year from end of treatment or until death. Once 
disease progression is documented, subjects will be followed ev ery 3 months for 1 year from th e time of documented progression  or death.  
6 Medical History to include demographics, prior treatments, radi ation and surgical history, smoki ng history, and trial awarenes s question. 
Diagnosis and staging to include pathology report and Tumor Nod e Metastasis (TNM) staging. 
7Vital signs to include blood pr essure, weight, and height (scre ening only) and ECOG performance status 
8CMP with liver function tests ( LFTs) to include sodium, potassi um, chloride, creatinine, blood urea nitrogen, AST, ALT, total bilirubin, alkaline 
phosphatase. 
9For women of childbearing potential (WOCBP): urine or serum βhC G, within 7 days prior to study registration and within 72 hour s prior to 
receiving the first dose of study medication.  If a urine test is done and it is positive or cannot be confir med as negative, a serum pregnancy test will 
be required. 
10Tumor response assessment will be p erformed every odd numbered cycle starting with cycle 3; tumo r imaging to be done at treatm ent 
discontinuation at discretion of investigator. Subjects with on going response or stable disease after 1 year on study drug may  reduce tumor 
response frequency to every 3 or 4 cycles (9 or 12 wks) at the discretion of the treating physician. Chest CT  should include the upper abdomen 
including the adrenals and liver. Baseline (and subsequent) CT or MRI of abdomen and pelvis  is required only for subjects with known 
abdominal or pelvic metastasis. MRI of brain  should be performed at screening as per Section 3.2.2. Baseline bone scan  will be obtained at 
discretion of investigator. PET-CT scans may be used for in itial staging or f ollow-up imagi ng in place of standard CT scans at the discretion of the 
treating physician.  
11Partner chemotherapy drug, chosen  at discretion of investigator , will be either docetaxel, gemc itabine or pemetrexed [for non- squamous only]. If 
gemcitabine is chosen, dosing w ill be on D1 and D8 of each cycl e. 
12Fixed paraffin-embedded blocks/s lides will be requested from ti ssue obtained prior to initial treatment with PD-1 inhibitor. 
13Optional biopsies will be requ ested at time of progression on P D-1 or PD-L1 inhibitor (study e ntry) and at time of progression  on combination of 
pembrolizumab and chemothera py (safety follow up visit) 
14Blood samples will be collected to support biomarker research.  See Clinical Laboratory Manual (CLM) for additional details. 
15Submission of whole blood for banking is to be collected at Pre -Treatment Cycle 1 Day 1. See CLM for collection, processing, l abeling and 
shipping instructions. 
16Submission of unstained slides for banking from an archived FFP E tumor block (if available). S ee CLM for collection, labeling,  and shipping 
instructions. 
17Submission of serum and plasma for banking are to be collected at Pre-Treatment Cycle 1 Day 1 a nd at the 30-Day Safety Follow up visit. See 
CLM for collection, labeling , processing, and shipping instruct ions. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 36 of 66 A window of ±3 days will be applie d to all treatment study visi ts; a window of ±7 days will be 
applied to all safety follo w-up visits and tum or imaging. 
7.1 Screening Evaluations 
7.1.1 Within 28 days prior to registrat ion for protocol therapy 
 Informed consent, HIPAA authorization 
 Medical history to include demogr aphics, prior treatments, radi ation and surgical 
history, and trial aw areness question. 
 Smoking history to include: amoun t, frequency, start and stop d ates of cigarette, cigar 
and pipe usage.  
 Diagnosis and staging to include pathology report and Tumor Nod e Metastasis (TNM) 
staging 
 Physical exam 
 Vital signs (blood pressure, wei ght, and height [screening only ] and ECOG 
performance status) 
 AEs, ECIs & concomitant medications 
 Complete blood cell co unt with differential 
 Comprehensive metabolic profile ( sodium, potassium, chloride, c reatinine, blood urea 
nitrogen; liver function tests (L FTs) to include AST, ALT, tota l bilirubin, alkaline 
phosphatase) 
 Thyroid function (TSH, T4, free T3) 
 [-7 days] Pregnancy test (serum or urine) for women of childbea ring potential 
(WOCBP) 
 Baseline Disease Evaluation 
Tumor response assessment will consist of evaluation by CT scan s of chest and MR or CT 
of abdomen and pelvis. Subject imaging modality should remain t he same throughout the 
study. PET-CT scans may be used for initial staging or follow-up imagi ng in place of 
standard CT scans at the discr etion of the treating physician.  
 CT chest: should include the uppe r abdomen including the adrena ls and liver 
 CT or MRI of abdomen and pelvis: required only for subjects wit h known abdominal 
or pelvic metastasis 
 MRI of brain, if indicated. See Section 3.2.2. 
 Bone/ PET scan: at discretion of investigator. 
 Optional Tumor Biopsy (See CL M for additional details) 
 Optional biopsy is requested a t the time of progression on PD-1  or PD-L1 inhibitor 
(study entry) 
  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 37 of 66 7.2 On Treatment Evaluations 
7.2.1 Cycle 1 Day 1 
Note:  Cycle 1 Day 1 lab testing need not be repeated if completed wi thin 7 days of starting 
protocol therapy. 
 Physical exam 
 Vital signs and ECOG performance status 
 AEs, ECIs & concomitant medications 
 Complete blood cell co unt with differential 
 Comprehensive metabolic profile  
 [-72 hours prior to first dose] P regnancy test (serum or urine)  for women of 
childbearing potential 
 Pembrolizumab plus chemo (physician’s choice) 
 Correlative samples: (See CLM for additional details) 
o Unstained slides from archived tissue 
o Pre-dose blood samples will be collected to support biomarker r esearch 
 Banking samples.  
o Whole blood 
o Unstained slides from archived tissue 
o Serum and plasma 
7.2.2 Cycle 1 Day 8 (if applicable) 
 Complete blood cell co unt with differential 
 Gemcitabine administration  
7.2.3 Cycle 2+ Day 1 
 Physical exam 
 Vital signs and ECOG performance status 
 AEs, ECIs & concomitant medications 
 Complete blood cell co unt with differential 
 Comprehensive metabolic profile  
 Pembrolizumab plus chemo (physician’s choice) 
7.2.4 Cycle 2+ Day 8 (if applicable) 
 Complete blood cell co unt with differential 
 Gemcitabine administration  
7.2.5 Day 1 of Every Other Cycle starting with Cycle 3 
 Thyroid function (TSH, T4, free T3) 
 CT chest 
 CT or MRI of abdomen and pelvis 
 Bone/ PET scan: at discretion of investigator 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 38 of 66 7.3 Safety Follow-up Evaluations 
A safety follow-up visit should o ccur when subjects permanently  stop study treatment for 
whatever reason (toxicity, pr ogression, or at discretion of sit e investigator) and should be 
performed 30 days (±7 days) after  the last dose of treatment. S ubjects who have an ongoing ≥ 
grade 2 or serious AE (SAE) at t his visit will continue to be f ollowed until the AE resolves to ≤ 
Grade 1 or baseline, deemed clini cally insignifi cant, and/or un til a new anti-cancer treatment 
starts, whichever is earlier.  
 Physical exam 
 Vital signs and ECOG performance status 
 AEs, ECIs & concomitant medications 
 Complete blood cell co unt with differential 
 Comprehensive metabolic profile  
 
Optional Tumor Biopsy (See CL M for additional details) 
 Optional biopsy is requested a t the time of progression on comb ination of pembrolizumab 
and chemotherapy (safety follow up visit) 
7.4 Long Term Follow-up Evaluations 
All subjects will be followed until documented disease progress ion.  Subjects who discontinue 
treatment for any reason without  documented disease progression  will be followed for disease 
progression every 3 months for 1 y ear from end of treatment or until death, whichever occurs 
first.  
 AEs, ECIs & concomitant medications 
 CT chest 
 CT or MRI of abdomen and pelvis 
 
Once disease progression is documented, subjects will enter a s urvival follow up period every 3 
months for 1 year from the time  of documented progression or de ath, whichever occurs first.  
Follow up may be accomplished via  clinic visit, phone call, or other avenues as appropriate. 
 
8. BIOSPECIMEN STUDIES AND PROCEDURES 
Please refer to the CLM for all  sample collection, processing, labeling, and shipping instructions. 
8.1 Tissue for assessment of PD-L1 status 
8.1.1 Archival  
 Prior to initial treat ment with PD-1 inhibitor 
8.1.2 Optional Biopsies 
 At time of progression on PD-1 or  PD-L1 inhibitor (study entry)  
 At time of progression on combi nation of pembrolizumab and chem otherapy (safety 
follow up visit) 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 39 of 66 8.2 Tissue for genetic analysis 
 NeoTYPE Lung Tumor Profile Genetic Analysis will also be perfor med: Sequencing of 
select exons of AKT1, BRAF, EGF R, ERBB2, ERBB4, FGFR1, FGFR2, F GFR3, KIT, 
KRAS, MET, NOTCH1, NRAS, PDGFRA,  PIK3CA, PTEN, SMAD4, SMO, SRC,  
TP53, as well as ALK FISH, HER2 F ISH, MET FISH, PTEN FISH, RET FISH, ROS1 
FISH. 
8.3 Blood for Somatic Baseline DNA 
 Peripheral blood will be drawn for  somatic baseline DNA by Neog enomics in accordance 
with the NeoTYPE Lung Tumor  Profile (tissue test). 
8.4 Blood for proteomic analysis and lipidomic profiling 
 Pre-treatment blood samples will be used to explore the associa tion of proteomic and 
lipidomic tests at baseline w ith ORR, PFS, and clinical benefit  rate. Refer to the CLM for 
collection, processing, labeli ng and shipping instructions. 
8.5 Confidentiality of Biospecimens 
Samples that are collected w ill be identified by a subject’s st udy number assigned a t the time of 
registration to the trial. Any mat erial issued to collaborating  researchers will be anonymized and 
only identified by the sub ject’s study number. 
8.6 Samples for future studies 
Subject consent will be obtained for additional samples collect ed for future Big Ten CRC 
studies. HCRN, as Administrative Headquarters for the Big Ten C RC, will manage the banked 
samples. Samples will be banked i ndefinitely in t he HCRN Biorep ository.  
 This includes: 
 Whole blood: Whole blood will be c ollected prior to treatment o n Cycle 1 Day 1.  
 Pre- and Post-treatment plasma: W hole blood for plasma will be collected prior to treatment 
on Cycle 1 Day 1 and at Safety Follow Up visit.  
 Pre- and Post-treatment serum: Whole blood for serum will be co llected prior to treatment on 
Cycle 1 Day 1 and at Safety Follow Up visit. 
 Unstained slides: Unstained slides will be obtained from the su bject’s archived formalin fixed 
paraffin embedded tumor sample.  
 
9. CRITERIA FOR DISEASE EVALUATION 
9.1 Measurable Disease 
Measurable disease is defined as the presence of at least one m easurable lesion. Measurable 
lesions are defined as those that can be accurately measured in  at least one dimension (longest 
diameter to be recorded) as > 20 mm by chest x-ray, as >10 mm wi
th CT scan, or >10 mm with 
calipers by clinical exam.  All tumo r measurements must be reco rded in millimeters (or decimal 
fractions of centimeters). 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 40 of 66 9.1.1 Malignant Lymph Nodes 
To be considered pathologically e nlarged and measurable, a lymp h node must be >15 mm in 
short axis when assessed by CT s can (CT scan slice thickness re commended to be no greater 
than 5 mm).  At baseline and i n follow-up, only the  short axis will be measured and followed. 
9.2 Non-measurable Lesions 
All other lesions (or sites of di sease), including small lesion s (longest diameter <10 mm or 
pathological lymph nodes with ≥  10 to <15 mm short axis), are c onsidered non-measurable 
disease.  Bone lesions, leptome ningeal disease, ascites, pleura l/pericardial effusions, 
lymphangitis cutis/pulmonitis, in flammatory breast disease, and  abdominal masses (not followed 
by CT or MRI), are conside red as non-measurable. 
 NOTE:   Cystic lesions that meet the c riteria for radiographically de fined simple cysts should not 
be considered as malignant lesi ons (neither measurable nor non- measurable) since they are, by 
definition, simple cysts. ‘Cys tic lesions’ thought to represent  cystic metastases can be considered 
as measurable lesions, if they m eet the definition of measurabi lity described above. However, if 
non-cystic lesions are present i n the same subject, these are p referred for sele ction as target 
lesions. 
9.3 Target Lesions 
All measurable lesions up to a  maximum of 2 lesions per organ a nd 5 lesions in total, 
representative of all involve d organs, should be identified as target lesions and recorded and 
measured at baseline.  Target lesions should be selected on the  basis of their size (lesions with 
the longest diameter), be represe ntative of all  involved organs , but in addition should be those 
that lend themselves to reproduc ible repeated measurements.  It  may be the case that, on 
occasion, the largest lesion does not lend itself to reproducib le measurement in which 
circumstance the next l argest lesion which can be measured repr oducibly should be selected.  A 
sum of the diameters (longest  for non-nodal lesions, short axis  for nodal lesions) for all target 
lesions will be calculated and re ported as the baseline sum dia meters.  If lymph nodes are to be 
included in the sum, then only the  short axis is added into the  sum.  The baseline sum diameters 
will be used as reference to fur ther characterize any objective  tumor regression in the measurable 
dimension of the disease. 
9.4 Non-target Lesions 
All other lesions (or sites of di sease) including any measurabl e lesions over and above the 5 
target lesions should be identif ied as non-target lesions and s hould also be record ed at baseline.  
Measurements of these lesions a re not required, but the presenc e, absence, or in rare cases 
unequivocal progression of eac h should be noted throughout foll ow-up. 
9.5 Evaluation of Target Lesions 
NOTE:  In addition to the informatio n below, also see section 4.3.2 i
n the international criteria 
proposed by the Response Evaluation  Criteria in Solid Tumors (R ECIST) Committee, version 
1.1 (Eur J Cancer 45;2009:228-247)  for special notes on the ass essment of target lesions.  
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 41 of 66 Complete 
Response (CR) Disappearance of all target les ions.  Any pathological lymph 
nodes (whether target or non-targ et) must have reduction in 
short axis to <10 mm.
Partial Response (PR) At least a 30% decrease in the s um of the diameters of target 
lesions, takin
g as reference the baseline sum diameters 
Progressive Disease (PD) At least a 20% increase in the s um of the diameters of target 
lesions, taking as reference th e smallest sum on study (this 
includes the baseline sum if th at is the smallest on study).  I n 
addition to the relative increas e of 20%, the sum must also 
demonstrate an absolute increa se of at least 5 mm.  (Note:  the  
appearance of one or more new lesions is also considered 
pro
gressions).
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR  nor sufficient 
increase to qualify for PD, taki ng as reference th e smallest su m 
diameters while on stud
y
9.6 Evaluation of Non-target Lesions 
Complete 
Response (CR) Disappearance of all non-targe t lesions and normalization of 
tumor marker level .  All lymph nodes must be non-pathological 
in size (<10 mm short axis)  Note:  If tumor markers are in itially above the upper normal 
limit, they must norma lize for a subject to be considered in 
complete clinical response.
Non-CR/ Non-PD Persistence of one or more non- target lesion(s) and/or 
maintenance of tumor marker level above the  normal limits 
Progressive 
Disease (PD) Appearance of one or more new lesions and/or unequivocal 
progression of existing non-ta rget lesions.  Unequivocal 
progression should not normally tru mp target lesion status.  It  
must be representative of overa ll disease status change, not a 
single lesion increase.
 Although a clear progression of “no n-target” lesions only is ex ceptional, the opinion of the site 
investigator should prevail in s uch circumstances, and the prog ression status should be 
confirmed at a later time by the sponsor investigator. 
9.7 Evaluation of Best Overall Response 
Target Lesions Non-Target Lesions New LesionsOverall 
Response 
CR CR No CR 
CR Non-CR/ Non-PD No PR 
CR Not evaluated No PR 
PR Non-PD/ or not all 
evaluated No PR 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 42 of 66 SD Non-PD or not all evaluated No SD 
Not all evaluated Non-PD No Non-evaluable 
PD Any Yes or No PD 
Any PD* Yes or No PD 
Any Any Yes PD 
*In exceptional circumstances, unequivocal progression in non-t arget lesions may be 
accepted as disease progression.
Subjects with a global deteriora tion of health status requiring  discontinuation of treatment 
without objective evidence of dis ease progression at that time should be classified as having 
“symptomatic deterioration”.  E very effort should be made to do cument the objective 
progression even after dis continuation of treatment. 
 In some circumstances it may be di fficult to dist inguish residu al disease from normal tissue.  
When the evaluation of complete response depends on this determ ination, it is r ecommended that 
the residual lesion be investigat ed (fine needle aspirate/biops y) to confirm the complete response 
status.  
9.8 Definitions for Response Evaluation – RECIST 1.1 
9.8.1 First Documentation of Response 
The time between initiation of t herapy and first documentation of PR or CR. 
9.8.2 Confirmation of Response 
To be assigned a status of compl ete or partial response, change s in tumor measurements must be 
confirmed by repeat assessments  performed no less than four wee ks after the criteria for response 
are first met. 
9.8.3 Duration of Response 
Duration of overall response—the period measured from the time that measurement criteria are 
met for complete or partial res ponse (whichever status is recor ded first) until the date that 
recurrent or progressive diseas e is objectively do cumented (tak ing as reference for progressive 
disease the smallest measurement s recorded since treatment star ted). 
9.8.4 Duration of Overall Complete Response 
The period measured from the time that measurement criteria are  met for complet e response until 
the first date that recurrent di sease is objectively documented . 
9.8.5 Objective Response Rate  
The objective response rate is the proportion of all subjects w ith confirmed PR or CR according 
to RECIST 1.1, from the start of  treatment until disease progre ssion/recurrenc e (taking as 
reference for progressi ve disease the smalle st measurements rec orded since the start of 
treatment). 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 43 of 66 9.8.6 Disease Control Rate:  
The disease control rate is the proporti on of all subjects with  stable disease (SD) for 8 weeks, or 
partial response (PR), or complete response (CR) according to R ECIST 1.1, from the start of 
treatment until disease progression/recurrence (taking as refer ence for progressive disease the 
smallest measurements recorded s ince the start of treatment). 
9.8.7 Time to Progression: 
A measurement from the date of treatment start until the criter ia for disease progression is met as 
defined by RECIST 1.1. Subjects w ho have not progressed or have  died due to any cause will be 
right-censored at the date of the  last disease evaluation or da te of death. 
9.8.8 Progression Free Survival 
A measurement from the date of treatment start until the criter ia for disease progression is met as 
defined by RECIST 1.1 or death occ urs. Subjects who have not pr ogressed will be right-censored 
at the date of the las t disease evaluation. 
9.8.9 Overall Survival 
Overall survival is defined by t he date of treatment start to d ate of death from any cause. 
 9.9 Immune- Related RECIST Criteria 
Please refer to the full public ation for comple te details on im mune-related RECIST criteria: 
Bohnsack O. et al. Adaptation of the immune-related response cr iteria: irRECIST. ESMO 2014 
Abstract 4958. http://www.irrecist.com/  
9.9.1 Measurable lesion definitions and target lesion selection 
Follow the definitions from RECIST 1.1.  
 Measurable lesions must be accu rately measured in at least one dimension with a minimum size 
of: 
 10 mm in the longest diameter by C T or MRI scan (or no less tha n double the slice 
thickness) for non-nodal lesions a nd ≥15 mm in short axis for n odal lesions 
 10 mm caliper measure ment by clinical exam 
 20 mm by chest X-ray 
 
9.9.2 Baseline: Non-measurable lesion definitions 
Follow the definitions from RECIST 1.1. 
 Non-target lesions will include:  
 Measurable lesions not selected as target lesions  
 All sites of non-measurable dis ease, such as neoplastic masses that are too small to 
measure because their longest uni nterrupted diame ter is < 10 mm  (or < two times the 
axial slice thickness), ie. the  longest perpendicular diameter is ≥10 and < 15 mm.  
 Other types of lesions that are confidently felt to represent n eoplastic tissue, but are 
difficult to measure in a repr oducible manner. These include bo ne metastases, 
leptomeningeal metastases, mali gnant ascites, ple ural or perica rdial effusions, ascites, 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 44 of 66 inflammatory breast disease, lym phangitis cutis/pulmonis, cysti c lesions, ill-defined 
abdominal masses, skin lesions, etc.  
9.9.3 Baseline: Target and Non-Target  Lymph Node Lesion Definitions 
Follow the definitions from RECIST 1.1. 
9.9.4 Baseline: Bone Lesions 
Follow the definitions from RECIST 1.1.  
 Regardless of the imaging modal ity blastic bone lesions will no t be selected as target 
lesions. Lytic or mixed lytic-bla stic lesions with a measurable  soft tissue component ≥10 
mm can be selected as target lesions. 
9.9.5 Baseline: Brain Lesions 
 Brain lesions detected on brain sca ns can be considered as both  target or non-target 
lesions. 
9.9.6 Baseline: Cystic and necrotic lesions as target lesions 
 Lesions that are partially cysti c or necrotic can be selected a s target lesions. The longest 
diameter of such a l esion will be added to the Total Measured T umor Burden (TMTB) of 
all target lesions at baseline . If other lesions with a non-liq uid/non-necrotic component 
are present, those should be preferred. 
9.9.7 Baseline: Lesions with prior local treatment 
 During target lesion selection the radiologist will consider in formation on the anatomical 
sites of previous interventi on (e.g. previous irradiation, RF-a blation, TACE, surgery, 
etc.). Lesions undergoing prior intervention will not be select ed as target lesions unless 
there has been a demonstrati on of progress in the lesion. 
9.9.8 Baseline: No Disease at Baseline 
 If a patient has no measurable a nd no non-measurable disease at  baseline the radiologist 
will assign ‘No Disease’ (irND) a s the overall tumor assessment  for any available follow-
up timepoints unless new measurab le lesions are identified and contribute to the TMTB.  
9.9.9 Follow-up: Recording of Target and New Measurable Lesion Measur ements 
 The longest diameters of non-noda l target and new non-nodal mea surable lesions, and 
short axes of nodal target and new nodal measurable lesions wil l be recorded. Together 
they determine the Total Measure d Tumor Burden (TMTB) at follow -up. 
9.9.10  Follow-up: Definition of Measurable New Lesions:  
 In order to be selecte d as new measurable lesions (≤ 2 lesions per organ, ≤ 5 lesions total, 
per timepoint), new lesions must  meet criteria as defined for b aseline target lesion 
selection and meet the same mini mum size requirements of 10 mm in long diameter and 
minimum 15 mm in short axis fo r new measurable lymph nodes. New  measurable lesions 
shall be prioritized according t o size, and the largest lesions  shall be selected as new 
measured lesions. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 45 of 66 9.9.11  Follow-up: Non-Target Lesion Assessment 
 The RECIST 1.1 definitions for the  assessment of non-target les ions apply. The response 
of non-target lesions primarily c ontributes to the overall resp onse assessments of irCR 
and irNon-CR/Non-PD (irNN). Non- target lesions do not affect ir PR and irSD 
assessments. Only a massive a nd unequivocal worsening of non-ta rget lesions alone, 
even without progress in the T MTB is indicative of irPD. 
9.9.12  Follow-up: New Non-Measurable Lesions Definition and Assessment :  
 All new lesions not selected as ne w measurable lesions are cons idered new non-
measurable lesions and are follo wed qualitatively. Only a massi ve and unequivocal 
progression of new non-measurable  lesions leads to an overall a ssessment of irPD for the 
timepoint. Persisting new non-meas urable lesions prevent irCR. 
9.9.13  irRC Overall Tumor Assessments 
 Complete response (irCR) is de fined by the complete disappearan ce of all lesions. Lymph 
nodes must decrease to < 10 mm in  short axis. Confirmation of r esponse is not 
mandatory. 
 Partial response (irPR) is defi ned by the decrease of ≥ 30% in TMTB relative to baseline, 
non-target lesions are irNN , and no unequivocal progression of new non-measurable 
lesions.  
 Stable disease (irSD) is when t he measurements do not meet crit eria for irCR or irPR, in 
absence of progressive disease (irPD). 
 irNN is when no target disease was identified at baseline and a t follow-up the patient fails 
to meet criteria for irCR or irPD. 
 irPD is defined by a minimum 20% i ncrease and minimum 5 mm abso lute increase in 
TMTB compared to nadir, or irPD for non-target or new non-measu rable lesions. 
Confirmation of progression is r ecommended minimu m 4 weeks afte r the first irPD 
assessment. 
 
10. DRUG INFORMATION 
10.1 Pembrolizumab 
Please refer to the current vers ion of the Investigator’s Broch ure (IB) for additional information 
regarding this drug 
10.1.1  Supplier/How Supplied 
Merck will supply pembrolizumab a t no charge to s ubjects partic ipating in this c linical trial.  
 
The investigator sha ll take responsib ility for and shall take a ll steps to mainta in appropriate 
records and ensure a ppropriate supply, sto rage, handling, distr ibution, and usage of 
investigational product in accordance with the protocol and any  applicable laws and regulations. 
10.1.2  Preparation  
Please refer to the Pharmacy Manua l for a comprehensive descrip tion of pembrolizumab 
preparation. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 46 of 66  
Merck will supply pembrolizumab di rectly to sites at no cost to  subjects in this clinical trial.  
 The product after reconstitution wi th sterile water for injecti on and the liquid drug product is a 
clear to opalescent solution, which may contain extraneous and proteinaceous particulates. The 
reconstituted product and liquid product is intended for IV adm inistration. The reconstituted drug 
product solution and liquid drug product can be further diluted  with normal saline in IV containers 
made of polyvinyl chloride (PVC ) or non-PVC material. Reconstit uted vials should be 
immediately used to prepare the infusion solution in the IV bag  and the infusion solution should 
be immediately administered. If  not used immediately, vials and /or IV bags may be stored at 2-8 
°C for up to a cumulative time  of 20 hours. If refrigerated, th e vials and/or IV bags should be 
allowed to equilibrate to room temperature prior to subsequent use. Pembrolizumab solutions may 
be stored at room temperature for a cumulative time of up to 4 hours. This includes room 
temperature storage of reconsti tuted drug product solution and liquid drug produc t in vials, room 
temperature storage of infusi on solution in the IV bag and the duration of infusion. 
10.1.3  Storage and Stability 
Clinical supplies must be stor ed in a secure, limited-access lo cation under the storage conditions 
specified on the label.  Receipt and dispensing of trial medication must be recorded by an authorized person at the trial 
site.  Clinical supplies may not be us ed for any purpose other than th at stated in the protocol. 
10.1.4  Dispensing 
Pembrolizumab must be dispensed only from official study sites and to eligible subjects under 
the supervision of the si te investigator. Pembrolizumab sh ould be stored in a secure area  
according to local regulations.  It is the responsibility of th e site investigator to ensure that study 
drug is only dispensed to subjects.   
10.1.5  Adverse Events 
Please refer to the current vers ion of the Investigator’s Broch ure for a complete list of AEs. 
 Pembrolizumab is generally well tolerated and demonstrates a fa vorable safety profile in 
comparison to chemotherapy. Pembr olizumab is an immunomodulator y agent, and based on this 
mechanism of action, immune med iated adverse ev ents are of prim ary concern. Important 
identified risks for pembroliz umab monotherapy are primarily of  an immune mediate nature, 
and included the following in the last IB (edition 16): pneumon itis, colitis, hepatitis, nephritis, 
endocrinopathies that incl ude hypophysitis (including hypopitui tarism and secondary adrenal 
insufficiency), thyroid disorde r (hypothyroidism, hyperthyroidi sm and thyroiditis), Type I 
diabetes mellitis, uve itis, myositis, Guilla in-Barré syndrome, pancreatitis, myocarditis, 
myasthenic syndrome, encephaliti s, sarcoidosis, severe skin rea ctions including Stevens-
Johnson syndrome (SJS) and toxic ep idermal necrolysis (TEN), so me with fatal outcome; and 
“solid organ transplant rejec tion following pembrolizumab treat ment in donor organ recipients” 
(risk applicable to post-marke ting setting only, as such patien ts are currently excluded from 
Merck clinical trials with pembrolizumab).  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 47 of 66  
Immune-mediated adverse reactio ns (ARs), including severe and f atal cases, have occurred in 
patients receiving pembrolizuma b. Immune-mediated ARs can occur  after discontinuation of 
treatment. Immune-mediated ARs  affecting more than one body sys tem can occur 
simultaneously. In clinical studi es, most immune-mediated ARs w ere reversible and managed 
with interruptions of pembroliz umab, administra tion of corticos teroids, and/or supportive care. 
 The safety profile for pembroli zumab also includes 2 important potential risks – i .e. increased 
risk of severe complications (su ch as early severe graft versus  host disease and veno-occlusive 
disease) of allogeneic transplan t in patients with hematologic malignancies who have previously 
been treated with PD-1 inhibitors ; and GVHD after pembrolizumab  administration in patients 
with a history of allogeneic HSCT.  Since the last IB (Edition 16) , 1 new identified risk in the sp ecific population of RCC patients 
who receive the combination of pembrolizumab plus axitinib, has  been added to the safety 
profile for pembrolizumab. An inc rease in hepatic events (ie, i ncreased incidences of Grades 3 
and 4 elevated ALT and AST) was observed in RCC patients who re ceived the combination of 
pembrolizumab plus axitinib. Det ails are provided in section 5. 4.2.2 of the IB. The Grade 3 or 4 
ALT and AST elevations can be man aged with prompt interruption or discontinuation of both 
study treatments, close liver e nzyme and function monitoring, a nd with or without concomitant 
steroid treatment.  In addition to 1 new identified r isk in the RCC population rece iving the combination of 
pembrolizumab plus axitinib, bas ed upon additional information received from the clinical 
study and postmarketing environmen ts after release of IB Editio n 16, the following changes 
have been made to the safety in formation for pembrolizumab:  
 Information regarding exacerbati on of myasthenia gravis was add ed to product labeling 
to further characterize the ex isting risk of myasthenic syndrom e; 
 Information regardi ng primary adrenal insufficiency was added t o product labeling to 
further characterize the existi ng risk of immune-mediated endoc rinopathies; 
 A new adverse drug reaction of Vogt -Koyanagi-Harada syndrome wa s identified based 
primarily on postmarketing experien ce. Note: Vogt-Koyanagi-Hara da syndrome may 
include a constellation of signs/s ymptoms which are already lis ted in product labeling, 
namely, the existing AE of special  interest/risk of ‘uveitis’. However, considering the 
clinical significance of timely recognition and treatment of th e condition, and that the 
term was identified primaril y based on postmarketing experience , Merck decided to add 
the distinct preferred term of V ogt-Koyanagi-Harada syndrome to  the company core 
data sheet Postmarketin g Experience section. 
 A new ADR of hemophagocytic lym phohistiocytosis was identified based primarily on 
postmarketing experience. 
 Further details around frequency, r eporting, and ma nagement of immune-related AEs (irAEs) 
can be found in the current versi on of the Inves tigator’s Broch ure. In addition to the previously 
noted identified risks, infusi on-related reactions are a risk b ut are not considered immune 
mediated; these are also furth er described in the current IB. 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 48 of 66 10.2 Docetaxel 
NOTE : Please refer to the current pack age insert for complete presc ribing and toxicity 
information. Institutional guide lines may be used for preparati on and administration of this 
medication. 
10.2.1  Supplier/How Supplied  
Docetaxel is commercially available in single-dose vials contai ning 20 mg (0.5 ml) or 80 mg (2.0 
ml) docetaxel (anhydrous). 
10.2.2  Preparation  
Just prior to use, allow the docetaxel vial to reach room tempe rature for 5 minutes. Add the entire 
contents of the ethanol diluent vial and mix by gently rotating  the vial for 15 seconds. Allow to 
stand for 5 minutes at room tempe rature, and check that the sol ution is homogeneous and clear 
(persistent foam is normal). The  resulting solution contains 10  mg/mL of docetaxel. Please note 
that the solution cont ains 15% overfill. D osing amounts should be based in the c oncentration per 
extractable volume, not the total volume of the vial. The desir ed dose is diluted in D5W or NS. 
The volume of the infusion should be adjusted in order to have a final docetaxel concentration of 
between 0.3 mg/mL and 0.9 mg/mL. Non-PVC-containing intravenous  infusion bags and 
administration sets should be us ed to avoid patient exposure to  the plasticizer DEHP. 
10.2.3  Storage and Stability  
Docetaxel is stored at 4oC protected from light. The solvent vi als may be stored at room temperature 
or at 4oC. The premix  solution is stable for 8 hours at room te mperature (15o - 25oC) or refrigerated (at 
2o- 8oC). The final dilution is also stable for 8 hours. (Pleas e note that the company is no longer 
recommending that the final product be placed in PVC bags). 
10.2.4  Incompatibilities  
Intravenous bags and administration sets containing DEHP (di-[2 -ethylexyl] phthalate). No further 
information is available.  
10.2.5  Side Effects  
1. Cardiac: arrhythmias, pericard ial effusions, pa lpitations.  
2. Hematologic: dose-related neutr openia, leukopenia, thrombocytop enia, anemia, hypoglycemia, 
hypernatemia.  
3. Gastrointestinal: nausea and vo miting, diarrhea , oral mucositis , pancreatitis, esophagitis.  
4. Neurologic: reversible dysthesias  or paresthesias, peripheral n europathy, mild or moderate lethargy 
or somnolence, headache, seizures.  
5. Hypersensitivity: hypersensitivity  (local or general skin rash,  flushing, pruritus, drug-fever, chills 
and rigors, low back pain), severe anaphylactoid reactions (flu shing with hypo- or hypertension, 
with or without dyspnea).  
6. Dermatologic: alopecia, desquamation following localized prurig inous maculopapular eruption, 
skin erythema with edema, extravasation reaction (erythema, swe lling, tenderness, pustules), 
reversible peripheral phlebitis, nail changes.  
7. Hepatic: increased transaminase, alkaline phosphatase, bilirubi n; hepatic failure; hepatic drug 
reaction.  
8. Pulmonary: dyspnea with restrictiv e pulmonary syndrome, pleural  effusions.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 49 of 66 9. Other: asthenia, dysgeusia, anorexia, conjunctivitis, arthralgi a, muscle aches, myopathy, 
peripheral edema, fluid retenti on syndrome, ascites, flu-like s ymptoms, fever. 
 
10.3 Pemetrexed Disodium Heptahydrate (Alimta)  
NOTE: Please refer to the current packag e insert for complete prescri bing and toxicity 
information. Institutional guide lines may be used for preparati on and administration of this 
medication. 
10.3.1  Supplier/How Supplied  
Pemetrexed is commercially available.  
 Pemetrexed is supplied as a ster ile lyophilized powder for intr avenous infusion available in 
single-dose vials. The product is  a white to either light yello w or green-yellow lyophilized solid. 
Pemetrexed is supplied in 100m g and 500 mg vials. Each 500-mg v ial of pemetrexed contains 
pemetrexed disodium equivalen t to 500 mg pemetrexed and 500 mg of mannitol. Each 100-mg 
vial of pemetrexed d isodium contains equivalent to 100mg pemetr exed and 106mg of mannitol. 
Hydrochloric acid and/or sodi um hydroxide may have been added t o adjust pH.  
10.3.2  Preparation 
1. Use aseptic technique during the reconstitution and further dil ution of pemetrexed for 
intravenous infusi on administr ation.  
2. Calculate the dose and the numbe r of pemetrexe d vials needed. E ach vial contains 500 mg 
or 100mg of Pemetrexed. The vial con tains an excess of Pemetrex ed to facilitate delivery of 
label amount.  
3. Reconstitute 500-mg vials wit h 20 mL of 0.9% Sodium Chloride In jection (preservative 
free) to give a solution contai ning 25 mg/mL Pemetrexed. Gently  swirl each vial until the 
powder is completely dissolved, reconstitute 100mg vials with 4 .2 ml of 0.9% Sodium 
Chloride injection (preservative free) to give a Solution conta ining 4.3 mg/ml pemetrexed. 
The resulting solution is clear  and ranges in color from colorl ess to yellow or green-yellow 
without adversely affecting produc t quality. The pH of the reco nstituted pemetrexed 
solution is between 6.6 and 7.8. FURTH ER DILUTION IS REQUIRED.  
4. Parenteral drug products should be i nspected visually for parti culate matter and 
discoloration prior to a dministration. If particulate matter is  observed, do not administer.  
5. The appropriate volume of recons tituted Pemetrexed solution sho uld be further diluted to 
100 mL with 0.9% Sodium Chloride In jection (prese rvative free) and administered as an 
intravenous infusion over 10 minutes. 
6. Chemical and physical stabilit y of reconstituted and infusion s olutions of pemetrexed were 
demonstrated for up to 24 hours fo llowing initial reconstitutio n, when stored at refrigerated 
or ambient room temperature [see USP Controlled Room Temperatur e] and lighting. When 
prepared as directed, reconstitution and infusion solutions of pemetrexed contain no 
antimicrobial preservatives. D iscard any unused portion. Recons titution and further dilution 
prior to intravenous infusi on is only recommended with 0.9% Sod ium Chloride Injection 
(preservative free). Pemetrexed i s physically incompatible with  diluents containing calcium, 
including Lactated Ringer’s Inj ection, USP and Ringer’s Injecti on, USP and therefore these 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 50 of 66 should not be used. Co-administr ation of pemetrexed with other drugs and diluents has not 
been studied, and therefore is not recommended. 
10.3.3  Storage and Stability 
Pemetrexed for injection, should be stored at 25°C (77°F); excu rsions permitted to 15-30°C (59-
86°F). Chemical and physical stability of reconstituted and inf usion solutions of pemetrexed were 
demonstrated for up to 24 hours following initial reconstitutio n, when stored refrigerated, 2-8°C 
(36-46°F), or at 25°C (77°F), ex cursions permitted to 15-30°C ( 59-86°F). When prepared as 
directed, reconstituted and infu sion solutions of Pemetrexed co ntain no antimicrobial 
preservatives. Discard unused por tion. Pemetrexed is not light sensitive. 
10.3.4  Incompatibilities and Pote ntial Drug Interactions  
Ibuprofen — Daily ibuprofen doses of 400 mg QID reduce pemetrexed’s clear ance by about 20% 
(and increase AUC by 20%) in pat ients with normal renal functio n. The effect of greater doses of 
ibuprofen on pemetrexe d PK is unknown. Pemetr exed is primarily eliminated unchanged renally 
as a result of glomerular filt ration and tubular secretion. Con comitant administration of 
nephrotoxic drugs could result in  delayed clearance of pemetrex ed. Concomitant administration 
of substances that are also tubularly secreted (e.g., probeneci d) could potentially result in delayed 
clearance of pemetrexed. Although ibuprofen (400 mg QID) can be  administered with pemetrexed 
in patients with normal renal func tion (creatinin e clearance (8 0 mL/min), caution should be used 
when administering ibuprofen conc urrently with pemetrexed to pa tients with mild to moderate 
renal insufficiency (creatinine clearance from 45 to 79 mL/min) . Patients with mild to moderate 
renal insufficiency should avoid taking NSAIDs with short elimi nation half-lives for a period of 
2 days before, the day of, and 2 days following administration of pemetrexed. In the absence of 
data regarding potential interact ion between pemetrexed and NSA IDs with longer half-lives, all 
patients taking these NSAIDs shoul d interrupt dos ing for at lea st 5 days before, the day of , and 2 
days following pemetrexed adminis tration. If concomitant admini stration of an NSAID is 
necessary, patients should be mon itored closely for toxicity, e specially myelosuppression, renal, 
and gastrointestin al toxicity.  
10.3.5  Side Effects  
1. Renal: creatinine elevation (10%)  
2. Neurologic: neuropathy-sensory ( 9%), taste disturbance (8%)  
3. Hematologic: anemia (33%), neutropenia (29%), leucopenia (18%),  thrombocytopenia (10%)  
4. Gastrointestinal: nausea (56%),  vomiting (40%), anorexia (27%),  constipation (21%), 
stomatitis/pharyngitis (14%), dia rrhea (12%), dyspepsia/heartbu rn (5%)  
5. Dermatology/skin: al opecia (12%), rash/desquamation (7%)  
6. Other: fatigue, febrile neutr openia, infection, pyrexia, dehydr ation, increased AST, increased 
ALT, creatinine clearance decrease, renal failure, conjunctivit is, arrhythmia, chest pain, 
increased GGT, motor neuropathy 
 
10.4 Gemcitabine 
NOTE: Please refer to the current packag e insert for complete prescri bing and toxicity 
information. Institutional guide lines may be used for preparati on and administration of this 
medication. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 51 of 66 10.4.1  Supplier/How Supplied 
Gemcitabine is commerciall y available in 200 mg and 1 gm vials.  
10.4.2  Preparation 
Reconstitute the 200 mg vial wit h 5ml and the 1 gm vial with 25  ml preservative free normal 
saline to make a solution cont aining 38 mg/ml. Shake to dissolv e. 
10.4.3  Storage and Stability 
Unreconstituted drug vials are s tored at controlled room temper ature. Reconstituted solution 
should be stored at controlled r oom temperature and used within  24 hours. Solutions of 
gemcitabine should not be refriger ated; crystalli zation may occ ur. The unused portion should be 
discarded. 
10.4.4  Side Effects 
1. Hematologic: Neutropenia, ane mia, thrombocytopenia, and leukope nia are reported. 
2. Dermatologic: A rash is seen i n about 25% of patients and is as sociated with pruritus in 
about 10% of patients. The rash is usually mild, not dose-limit ing, and responds to local 
therapy. Desquamation, vesicula tion, and ulceration have been r eported rarely. Alopecia is 
usually minimal. Injec tion-site reactions. 
3. Gastrointestinal: Nausea and vom iting are reported in about two -thirds of patients and 
requires therapy in about 20% of pa tients. It is rarely dose-li miting, and is easily 
manageable with standard antieme tics. Diarrhea, constipation, m ucositis. 
4. Hepatic: Abnormalities of hepatic transaminase enzymes occur in  two-thirds of patients, but 
they are usually mild, nonprogressive, and rarely necessitate s topping treatment. However, 
gemcitabine should be used with caution in patient s with impair ed hepatic function. 
5. Pulmonary: In clinical tria ls, dsypnea, unrelated to underlying  disease, has been reported in 
association with Gemzar thera py. Dyspnea was occasionally accom panied by 
bronchospasm. Pulmonary toxicit y has been reported with the use  of Gemzar. [Parenchymal 
toxicity, including interstitial pneumonitis, pulmonary fibrosi s, pulmonary edema, and adult 
respiratory distress syndrome ( ARDS) has been reported rarely f ollowing one or more doses 
of Gemzar administered to patien ts with various malignancies. S ome patients experienced 
the onset of pulmonary symptoms up to 2 weeks afte r the last Ge mzar dose. Respiratory 
failure and death occurred very rar ely in some patients despite  discontinuation of therapy.] 
The etiology of these effects is unknown. If such effects devel op, Gemzar should be 
discontinued. Early use of supporti ve care measures may help am eliorate these conditions. 
6. Neurologic: Somnolence, insom nia, paresthesia, pain. 
7. Cardiovascular: A few cases  of hypotension were reported. Some cases of myocardial 
infarction, congestive heart fail ure, and arrhythmias have been  reported. Peripheral edema is 
reported in about 30% of patients. S ome cases of facial edema h ave also been reported. 
Edema is usually mild to mode rate, rarely dose-limiting, someti mes painful, and reversible 
after stopping gemcitabine treatment. 
8. Other: Flu-like symptoms are r eported for about 20% of patients . This includes fever, 
headache, back pain, chills, myalg ia, asthenia, and anorexia. M alaise and sweating are 
reported. 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 52 of 66 11. ADVERSE EVENTS 
11.1 Definitions 
11.1.1  Adverse Event (AE) 
An AE is any untoward medical occu rrence whether or not conside red related to the study drug 
that appears to change in inte nsity during the course of the st udy. The following are examples of 
AEs:  
 Unintended or unfavorable sign or symptom 
 A disease temporally associate d with participa tion in the proto col 
 An intercurrent illnes s or injury that imp airs the well-being o f the subject 
 
Abnormal laboratory values or diag nostic test results constitut e AEs only if they induce clinical 
signs or symptoms or require tre atment or further diagnostic te sts   
 Hospitalization for elective surg ery or routine clinical proced ures that are not t he result of an 
AE (e.g., surgical insertion of central line) should not be rec orded as an AE.  
 Disease progression should not be  recorded as an AE, unless it is attributable to the study 
regimen by the site investigator. 
11.1.2  Serious Adverse Event (SAE) 
An SAE is an adverse event that: 
 Results in death.  
NOTE : Death due to disease progress ion should not be reported as a SAE, unless it is 
attributable by the site inve stigator to the study drug(s) 
 Is life-threatening (defined as an event in which the subject w as at risk of death at the 
time of the event; it does not r efer to an event which hypothet ically might have caused 
death if it were more severe) 
 Requires inpatient hospitaliza tion for >24 hours or prolongatio n of existing 
hospitalization.  NOTE:  Hospitalization for anticipate d or protocol specified procedur es such as 
administration of chemotherapy, cen tral line insertion, metasta sis interventional therapy, 
resection of primary tumor, or elective surgery, will not be co nsidered serious adverse 
events. 
 Results in persistent or significant disability/incapacity 
 Is a congenital anom aly or birth defect 
 Is an important medical event ( defined as a medical event(s) th at may not be immediately 
life-threatening or r esult in death or ho spitalization but, bas
ed upon appropriate medical 
and scientific judgment, may jeopa rdize the subject or may requ ire intervention (e.g., 
medical, surgical) to prevent  one of the other serious outcomes  listed in the definition 
above). Examples of such events include, but are not limited to , intensive treatment in an 
emergency room or at home for a llergic bronchospasm; blood dysc rasias or convulsions 
not resulting in hospitalization;  or the development of drug de pendency or drug abuse.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 53 of 66 11.1.3  Unexpected Adverse Event 
For this study, an AE is consider ed unexpected when it varies i n nature, intensity or frequency 
from information provided in the c urrent IB, package insert, or  when it is not included in the 
informed consent document as a po tential risk. Unexpected also refers to AEs that are 
mentioned in the IB as occurri ng with a class of drugs or are a nticipated from the 
pharmacological properties of  the drug, but are not specificall y mentioned as occurring with the 
particular drug under investigation.   
11.1.4  Relatedness 
AEs will be categorized according to the likelihood that they a re related to the study drug(s). 
Specifically, they will be categorized using the following term s:  
Unrelated The Adverse Event is not related  to the drug(s)  
Unlikely The Adverse Event is doubtfully related  to the drug(s)  
Possible The Adverse Event may be related  to the drug(s)  
Probable The Adverse Event is  likely related  to the drug(s)  
Definite The Adverse Event is clearly related  to the drug(s)  
11.2 Reporting 
11.2.1  Adverse Events 
 AEs will be recorded from time of registration until 30 days af ter discontinuation of study 
drug(s). 
 AEs will be recorded regardless  of whether or not they are cons idered related to the study 
drug(s).   
 All AEs will be recorded in the s ubject’s medical record and on  the appropriate study 
specific eCRF form within OnCore. 
 All AEs considered related to s tudy drug(s) will be followed un til resolution to ≤ Grade 1 
or baseline, deemed clinically i nsignificant, and/or until a ne w anti-cancer treatment 
starts, whichever occurs first. 
11.2.2  Definition and Reporting of a P embrolizumab Overdose:  
For purposes of this trial, an overdose will be defined as any dose exceeding the 
prescribed dose for pembroli zumab by 20% over the prescribed do se. No specific 
information is available on the t reatment of overdose of pembro lizumab. In the event of 
overdose, subject should be obser ved closely for signs of toxic ity. Appropriate 
supportive treatment should be prov ided if clinically indicated .  
 
 If an AE (s) is associated with ( “results from”) the overdose o f a Merck product, the 
AE(s) is reported as a SAE, e ven if no other seriousness criter ia are met. 
 If a dose of Merck’s product me eting the protocol definition of  overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 54 of 66 overdose is reported as a non- serious ECI, using the terminolog y “accidental or 
intentional overdose wi thout adverse effect.” 
 All reports of overdose with a nd without an AE must be reported  within 1 working day 
to Big Ten CRC Administrative He adquarters (AHQ). Big Ten CRC A HQ will report 
the event within 1 working day to M erck Global Safety (Attn: Wo rldwide Product 
Safety; FAX 215-993-1220). 
11.2.3  Reporting of Pregnancy and Lactation: 
Although pregnancy and lactation ar e not considered AEs, it is the responsibility of 
investigators or their design ees to report any pregnancy or lac tation in a subject 
(spontaneously reported to the m), including the pregnancy of a male subject’s female 
partner that occurs during the t rial or within 120 days of comp leting the trial, or 30 days 
following cessation of tr eatment if the subjec t initiates new a nticancer therapy, 
whichever is earlier. All subjec ts and female partners of male subjects who become 
pregnant must be followed to the  completion/termination of the pregnancy. Pregnancy 
outcomes of spontaneous aborti on, missed abortion, benign hydat idiform mole, blighted 
ovum, fetal death, intrauterine de ath, miscarriage, and stillbi rth must be reported as 
serious events (Important Medi cal Events). If the pregnancy con tinues to term, the 
outcome (health of infant) must also be reported. 
 Such events must be reported w ithin 1 working day to Big Ten CR C AHQ on the 
Pregnancy Report Form (See Docume nts/Info tab of the EDC). Big Ten CRC AHQ will 
report the event with in 1 working day to Merck Global Safety (A ttn: Worldwide Product 
Safety; FAX 215-993-1220). 
11.2.4  Definition and Reporting of Events of ECI: 
Selected non-serious and SAEs are also known as ECI and must be  recorded as such on 
the Adverse Event case report fo rms/worksheets and reported to Big Ten CRC AHQ 
within 1 working day of the event. ECI for this trial include: 
1. An overdose of Merck product, a s defined above, that is not ass ociated with clinical 
symptoms or abnormal laboratory results.  
2. An elevated AST or ALT lab value that is greater than or equal to 3 × the upper limit 
of normal, and an elevated total bilirubin lab va lue that is greater than or equal to 2 
× the upper limit of normal, and, at the same time, an alk aline phosphatase lab value 
that is less than 2 × the upper l imit of normal, a s determined by way of protocol-
specified laboratory testing or  unscheduled laboratory testing. * 
*NOTE:  These criteria are ba sed upon available regulatory guid ance documents. 
The purpose of the criteria is  to specify a threshold of abnorm al hepatic tests that 
may require an additional eval uation for an underlying etiology .  
 Subjects should be assessed for  possible ECIs prior to each dos e. Lab results should be 
evaluated and subjects should be a sked for signs and symptoms s uggestive of an 
immune-related event. Subjects who develop an ECI thought to be  immune-related 
should have additional testing to rule out other etiologic caus es. If lab results or 
symptoms indicate a possible immune-related ECI, then additiona l testing should be 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 55 of 66 performed to rule out other etio logic causes. If no other cause  is found, then it is 
assumed to be immune-related.   ECIs that occur in any subject from the date of first dose thro ugh 90 days following 
cessation of treatment, or 30 days  following cessation of treat ment if the subject initiates 
a new anticancer therapy, whichev er is earlier, whether or not related to the Merck’s 
product, must be reported withi n 1 working day to Big Ten CRC A HQ. Big Ten CRC 
AHQ will report the event withi n 1 working day to Merck Global Safety (Attn: 
Worldwide Product Safety; FAX 215-993-1220). 
11.2.5  Serious Adverse Events (SAEs) 
11.2.5.1  Site Requirements for Reporting S AEs to Big Ten CRC Administrat ive 
Headquarters 
 SAEs will be reported from time of registration until 90 days a fter discontinuation of 
study drug(s).  
 SAEs will be reported on the SAE  Submission Form and entered in  the SAE tab in 
OnCore  within  1 business day  of discovery of the event.   
 SAEs include events related a nd unrelated to the study drug(s).   
 All SAEs will be recorded in the s ubject’s medic al record and o n the appropriate study 
specific eCRF form within OnCore.   
 All SAEs regardless of relat ion to study drug wil l be followed until resolution to ≤ Grade 
1 or baseline and/or deemed clini cally insignifi cant and/or unt il a new anti-cancer 
treatment starts, whi chever occurs first. 
 Non-serious ECI will be reported to Big Ten CRC AHQ and will be  handled in the same manner as 
SAEs.   Additionally, any SAE, considere d by an investigator to be rela ted to either study drug, which is 
brought to the attention of  the investigator at any time outside of the 90-day tim e period specified 
in the previous paragraph, also m ust be reported immediately to  Big Ten CRC AHQ.  
 The site will submit the completed SAE Submission Form (see Doc uments/Info tab of the EDC) 
to Big Ten CRC AHQ within 1 business day of discovery of the event .  The form will be sent 
electronically to Big Ten CRC AHQ at SAFETY@hoosiercancer.org .  The site investigator is 
responsible for informing the I RB and/or other local regulatory  bodies as per local requirements. 
 The original copy of the SAE Repor t and the email correspondenc e or fax confirmation sheet 
must be kept within the st udy file at the study site. 
 Once the SAE has resolved (see resolution guidelines listed in 11.2.2.1), sites must submit a 
follow up SAE Submission Form with in a reasonable timeframe to Big Ten CRC AHQ at 
SAFETY@hoosiercancer.org . 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 56 of 66 11.2.5.2  Big Ten CRC AHQ Requirements f or Reporting SAEs to Merck 
Big Ten CRC AHQ will submit all i mmediately reportable events ( e.g. SAEs, ECIs, overdose, 
pregnancy, etc.) received fro m sites to Merck within 1 business day  of receipt of the SAE 
Reporting Form and to regulator y authorities (FDA) per federal guidelines.  
 Big Ten CRC AHQ will submit all S AE reports and any other relev ant safety information to: 
 Merck Global Safety (Attn: Worldwide Product Safety) at: Facsimile number:  +1-215-993-1220 
 Follow-up information will be pr ovided to Merck as reasonably r equested.   
11.2.5.3  Sponsor-Investigator Responsibilities 
Big Ten CRC AHQ will send a SAE s ummary to the sponsor-investig ator within 1 business day  
of receipt of SAE Submission For m from a site.  The sponsor-inv estigator will promptly review 
the SAE summary and assess for expectedness and relatedness. 
11.2.5.4  Big Ten CRC AHQ Responsibilities  for Reporting SAEs to FDA 
Big Ten CRC AHQ has been designat ed to manage the Investigation al New Drug Application 
(IND) associated with t his protocol on behalf  of the sponsor-in vestigator.  Bi g Ten CRC AHQ 
will cross-reference this submission to Merck’s parent IND at t he time of submission.  
Additionally, Big Ten CRC AHQ will submit a copy of these docum ents to Merck at the time of 
submission to FDA.  Big Ten CRC AHQ will be responsib le for all communication with the FDA in accordance with 
21CFR312 including but not limited  to the 7 and 15 Day Reports,  as well as an Annual Progress 
Report. Additionally, Big Ten CRC AHQ will submit a copy of the se reports to Merck at the 
time of submission to FDA. 
11.2.5.5  IND Safety Reports Unrelated to this Trial 
Merck will provide Big Ten CRC A HQ with IND safety reports from  external studies that 
involve the study drug(s) per thei r guidelines. Big Ten CRC AHQ  will forward the safety reports 
to the sponsor-investigator who w ill review these reports and d etermine if revisions are needed to 
the protocol or consent.  Big Ten CRC AHQ will forward these re ports to participating sites 
within 1 business day  of receiving the sponsor-inves tigator’s review. Based on the s ponsor-
investigator’s review, applicable changes will be made to the p rotocol and informed consent 
document (if required). All IND safety reports will also be mad e available to sites via OnCore. 
 Upon receipt from Big Ten CRC AHQ, s ite investigators (or desig nees) are responsible for 
submitting these safety reports  to their respective IRBs, as pe r their IRB policies. 
 
12. STATISTICAL METHODS 
Statistical analysis of this st udy will be the responsibility o f Biostatistics and Data Management 
Core at Indiana University Mel vin and Bren Simon Cancer Center (IUSCC). Parameter estimates 
and relevant summary statistics w ill be reported where appropri
ate. For continuous variables, 
summary statistics will include  number of subjects, mean, media n, standard deviation, minimum 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 57 of 66 and maximum. Categorical endpoints will be summarized using num ber of subjects, frequency, 
and percentages. Missing data wil l not be imputed. Data analysi s will be performed in SAS. 
 Additional exploratory analyses of the data will be conducted a s deemed appropriate. Changes 
from this analysis plan will not r equire an amendment to the pr otocol unless it changes a 
significant feature  of the protocol. 
12.1 Study Design 
This is a single-arm phase II study of continuation immunothera py with pembrolizumab 
following initial benefi t (CR, PR, or SD ≥ 3 months) with a PD- 1 or PD-L1 inhibitor. 
12.2 Endpoints 
12.2.1  Definition of Primary Endpoint 
The primary endpoint is PFS a ssessed by RECIST 1.1 and is defin ed as the time from date of 
treatment start until the criteria for disease progression is m et as defined by RECIST 1.1 criteria 
or death as a result of any cau se.  Those alive and without dis ease progression at the end of 
study follow-up will be censored at date of last disease assess ment.  
12.2.2  Definition of Secondary Endpoints 
Secondary endpoints are: 
 PFS assessed by irRECIST defined as the time from date of treat ment start until the 
criteria for disease progressi on is met as defined by irRECIST criteria or death as a result 
of any cause.  Those alive and with out disease progression at t he end of study follow-up 
will be censored at date of last disease assessment. 
 Objective response rate (CR+PR ) assessed via RECISIT 1.1 and ir RECIST 
 Clinical benefit rate (CR+PR+SD≥ 3 months) assessed via RECISIT 1.1 and irRECIST 
 OS defined as the time from date of treatment start until death  
 Toxicity assessed by CTCAE Version 4.   
12.3 Sample Size and Accrual 
 The historical control is a m edian PFS of 3 months (in the 2nd/ 3rd line setting).  
 Null hypothesis - Pembrolizumab pl us chemo will have a median P FS of 3 months.  
 Alternative hypothesis –Pembroliz umab plus chemo will have a me dian PFS of 6 months  
 
When the sample size is 31, a non- parametric tes t of median sur vival with a one-sided 0.05 
significance level will have 80%  power to detect the difference  between a median survival of 3 
months vs 6 months assuming an a ccrual period of approximately 
6 months (6 per month) and 
maximum follow-up of 1.5 years. To allow for replacement of pat ients who are not evaluable for 
efficacy (estimated to be 10%), up to 35 patients will be enrol led.  
12.4 Analysis Datasets 
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 58 of 66 Population Definition 
Enrolled This will comprise all subjects who meet the eligibili ty 
criteria and are regi stered onto the study.  
Efficacy This will comprise all subjects who receive at least o ne 
dose of trial treatment (both pembrolizumab and partner chemotherapy) and either undergo at least one post-baseline assessment or die  before any evaluation. 
Safety This will comprise all subjects that contribute data to the 
safety analysis including any patient who has received 
any treatment (incl uding partial treatme nt or single agent 
therapy).   
 
12.5 Assessment of Safety 
Safety will be assessed by the National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Ver sion 4. Please refer to the Study  Calendar for the schedule of 
toxicity assessment. 
12.6 Assessment of Efficacy 
All subjects who have received a t least one dose of treatment a nd have their disease re-evaluated 
will be evaluable for assessment of PFS and other efficacy outc omes. 
12.7 Data Analysis Plans 
12.7.1  Analysis Plans for Primary Objective 
PFS by RECIST 1.1 will be estimated  using Kaplan-Meier methodol ogy in the Efficacy 
population.  Median PFS of H
o:  3 months vs H a: 6 months by RECIST 1. 1 will be tested using 
a non-parametric test. 
12.7.2  Analysis Plans for Secondary Objectives 
In the Efficacy population, median PFS by irRECIST will be esti mated and tested similarly to 
the primary endpoint.  Objective re sponse rate and clinical ben efit rate will be estimated with 
two-sided 95% exact binomial conf idence intervals.  OS will be estimated using Kaplan-Meier 
methodology. Toxicities will be tabulated in the Safety populat ion. 
12.7.3  Analysis Plans for Exploratory Objectives 
In the Efficacy population, change i n tumor levels  of PD-L1 wil l be descriptively summarized 
and compared over time using pair ed t-tests.  Proportional haza rds regression (for PFS) and 
logistic regression (for ORR and c linical benefit rate) will be  used to correlate proteomic, 
lipidomic and genomic results  with clinical outcomes.  
12.7.4  Subgroup Analyses 
No subgroup analyses are planned. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 59 of 66 12.7.5  Other Planned Analyses 
For the Enrolled population, descriptive statistics will be use d the characterize subject 
demographic and clinical char acteristics, dis position, and sign ificant protocol violations.  In the 
Safety population, concomitant me dications and exposure will be  described. 
12.8 Interim Analysis/Crite ria for Stopping Study 
No formal interim safety or eff icacy analyses are planned. 
 
13. TRIAL MANAGEMENT 
13.1 Data and Safety Monitoring Plan (DSMP) 
The study will be conducted in accordance with Indiana Universi ty Melvin and Bren Simon 
Cancer Center’s (IUSCC) DSMP for High Risk Phase II Trials. 
 Big Ten CRC AHQ facilitated oversi ght activities for high risk phase II trials include: 
 Review and processing of all AEs requiring expe dited reporting as defined in the protocol 
 Provide trial accrual progress, s afety information, and data su mmary reports to the 
sponsor-investigator , including a weekly upda te of aggregate AE  data. For any 
increase in frequency of grad e 3 or above adverse events (above  the rate reported in 
the Investigator Brochure or p ackage insert), the sponsor inves tigator will notify Big 
Ten CRC AHQ who will not ify the DSMC Chair and Compliance Offic er 
immediately. The notific ation will include the incidence of stu dy adverse events, 
grades, and attributions, as we ll as investigator statements re garding comparison with 
risks per the IB/ package insert. 
 Notify participating sites of adve rse events pote ntially requir ing expedited reporting 
and subsequent DSMC recommenda tions for study modifications. 
 Investigators will conduct cont inuous review of data and patien t safety.  
 Coordinate monthly (Phase II) meetings which will include repre sentation from each 
accruing site. o These meetings should include r eview of data, the number of sub jects, and 
significant toxicities as describ ed in the protocol. Big Ten CR C AHQ should 
maintain meeting minutes and atten dance for submission to the D SMC upon 
request. 
 Conduct the trial acro ss all participating s ites in accordance with the requirements set forth in 
the IUSCC DSMP. 
13.2 
IUSCC Data Safety Monitor ing Committee Oversight 
The IUSCC Data and Safety Monitoring Committee (DSMC) is respon sible for oversight of 
subject safety, regulatory comp liance, and data integrity for t his trial. The DSMC will review this 
study to assess toxicity, complia nce, data inte grity, and accru al per the Institutional DSMP. Trials 
managed by Big Ten CRC AHQ are not routinely audited or monitor ed by IUSCC; however, the 
IUSCC DSMC retains the right  to audit Big Ten CRC AHQ trials on  a for cause basis. 
 The IUSCC DSMC will review stud y data bi-annually per the IUSCC  DSMP.   
 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 60 of 66 In preparation for the IUSCC DSMC review, Big Ten CRC AHQ will provide the IUSCC DSMC 
with the following: 
 Monthly summary reports 
 Reports of the following, if not a lready included in the Monthl y Summary Report: 
o Adverse event summary report (i ncluding serious adverse events)  
o Study accrual patterns  
o Protocol deviations 
 Audit and/or monitoring re sults, if applicable 
 Data related to stopping/decisi on rules described in study desi gn 
 Big Ten CRC meeting minutes/ attendance 
 
Documentation of DSMC reviews will be provided to sponsor-inves tigator and Big Ten CRC 
AHQ.  The IUSCC DSMC will notify the sponsor-investigator and o ther regulatory bodies, as 
appropriate, for issues of immediate concern.  The sponsor-inve stigator will work with Big Ten 
CRC AHQ to address the DSMC’s c oncerns as appropriate.   
 At any time during the  conduct of the trial , if it is the opini on of the sponsor inve stigator that the 
risks (or benefits) to the patie nt warrant early closure of the  study, this reco mmendation should 
be made in writing to the DSMC Chair and Compliance Officer. Al ternatively, the DSMC may 
initiate suspension or early c losure of the study based on its review of the study reports. 
13.3 IND Annual Reports 
As this trial has an IND held loc ally by the IU principal inves tigator, the IND A nnual Report will 
be prepared and submitted to the C ompliance Team. This report w ill be reviewed by the DSMC 
at the time of FDA submission. 
13.4 Data Quality Oversight Activities 
Remote validation of OnCore data  will be completed on a continu al basis throughout the life 
cycle of the study.  A summary rep ort (QC Report) of these chec ks together with any queries 
resulting from manual review of the eCRFs will be generated for  each site and transmitted to the 
site and the site monitor. Corrections will be made by the stud y site personnel. 
 Monitoring visits to the trial sites will be made periodically during the trial to ensure key aspects 
of the protocol are followed. Additional for-cause visits may o ccur as necessary. Source 
documents will be reviewed for ve rification of agreement with d ata entered into OnCore.  It is 
important for the site investigat or and their relevant personne l to be available for a sufficient 
amount of time during the monitori ng visits or audit, if applic able. The site investigator and 
institution guarantee access to s ource documents by Big Ten CRC  AHQ or its designee. 
 The trial site may also be subjec t to quality assurance audit b
y Merck or its designee as well as 
inspection by appropriate r egulatory agencies. 
13.5 Compliance with Trial Registration and Results Posting Requirem ents 
Under the terms of the Food and D rug Administra tion Modernizati on Act (FDAMA) and the 
Food and Drug Administration Amend ments Act (FDAAA), the sponso r-investigator of the trial 
is solely responsible for determin ing whether th e trial and its  results are subject to the 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 61 of 66 requirements for submission to t he Clinical Trials Data Bank, http://www.clinicaltrials.gov . The 
sponsor-investigator h as delegated responsibility to Big Ten CR C AHQ for registering the trial 
and posting the results on clin icaltrials.gov. Information post ed will allow subjects to identify 
potentially appropriate trials fo r their disease conditions and  pursue participation by calling a 
central contact number for furt her information on appropriate t rial locations and study site 
contact information.  
14. DATA HANDLING AND RECORD KEEPING 
14.1 Data Management 
Big Ten CRC AHQ will serve as the  Clinical Research Organizatio n for this trial . Data will be 
collected through the web-based c linical research platform, OnC ore, a system compliant with 
Good Clinical Practices and Feder al Rules and Regulations. Big Ten CRC AHQ personnel will 
coordinate and manage data for qua lity control assurance and in tegrity. All data wil l be collected 
and entered into OnCore
 by study site personnel from part icipating institutions.   
14.2 Case Report Forms and Submission 
Generally, clinical data will be e lectronically captured in OnC ore and correlative re sults will be 
captured in OnCore or other secure database(s). If  procedures on the study calenda r are 
performed for standard of care, a t minimum, that  data will be c aptured in the source document. 
Select standard of care data wil l also be captured in OnCore, a ccording to study-specific 
objectives. Please see the Data  and Safety Oversight Process (D SOP) guidelines for further 
details.   The completed dataset is housed at Big Ten CRC AHQ and is the s ole property of the sponsor-
investigator’s institution. It should not be made available in any form to third pa rties, except for 
authorized representatives of appr opriate Health/Regulatory Aut horities, without written 
permission from the sponsor-i nvestigator and Big Ten CRC AHQ. A fter the initial publication, 
the complete data set will be a vailable to all Big Ten CRC inst itutions. 
14.3 Record Retention 
To enable evaluations and/or aud its from Health Authorities/Big  Ten CRC AHQ, the site 
investigator agrees to keep record s, including the identity of all subjects (sufficient information 
to link records; e.g., hospital r ecords), all original signed i nformed consent forms, copies of all 
source documents, and detaile d records of drug disposition.  Al l source documents are to remain 
in the subject’s file and retai ned by the site investigator in compliance with local and federal 
regulations. No records will be  destroyed until Big Ten CRC AHQ  confirms destruction is 
permitted. 
14.4 Confidentiality 
There is a slight risk of loss  of confidentiality of subject in formation.  All record s identifying the 
subjects will be kept confidentia l and, to the extent permitted  by the applicable laws and/or 
regulations, will not b e made publicly available. Information c ollected will be maintained on 
secure, password protected electro nic systems. Paper files that  contain personal information will 
be kept in locked and secure lo cations only accessible to the s tudy site personnel.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 62 of 66  
Subjects will be informed in writi ng that some organizations in cluding the sponsor-investigator 
and his/her research associates , Big Ten CRC AHQ, Merck, IRB, o r government agencies, like 
the FDA, may inspect their medic al records to verify the inform ation collected, and that all 
personal information made avai lable for inspection will be hand led in strictest confidence and in 
accordance with local data protection laws.  If the results of the  study are published, t he subjects’s ident ity will remain confidential. 
15. ETHICS 
15.1 Institutional Review Board (IRB) Approval 
The final study protocol and the f inal version of the informed consent form must be approved in 
writing by an IRB.  The site investigator must submit written a pproval by the IRB to Big Ten 
CRC AHQ before he or she can enr oll subjects in to the study.   
 The site investigator is respons ible for informi ng the IRB of a ny amendment to the protocol in 
accordance with local requirements.  In addition, the IRB must approve all advertising used to 
recruit subjects for the study.  T he protocol must be re-approv ed by the IRB as local regulations 
require.   Progress reports and notifications of AEs will be provided to t he IRB according to local 
regulations and guidelines. 
15.2 Ethical Conduct of the Study 
The study will be performed in acco rdance with ethical principl es originati ng from the 
Declaration of Helsi nki. Conduct of the st udy will be in compli ance with ICH Good Clinical 
Practice, and with all applicab le federal (including 21 CFR par ts 56 & 50), state, or local laws. 
15.3 Informed Consent Process 
The site investigator will ensure the subject is given full and  adequate oral and written 
information about the nature , purpose, possible risks and benef its of the study.  S ubjects must 
also be notified they are free to disconti nue from the study at  any time.  The subject should be 
given the opportunity to ask quest ions and allowed time to cons ider the information provided. 
 The subject’s signed and dated i nformed consent must be obtaine d before conducting any 
procedure specifically for the s tudy.  The site investigator mu st store the original, signed 
informed consent form.  A copy of  the signed informed consent f orm must be given to the 
subject.  
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 63 of 66 16. REFERENCES 
 1. Siegel RL, Miller KD, Jemal  A. Cancer statistics, 2016. CA C ancer J Clin. 2016;66(1):7-
30. 
2. Howlader N, Noone A, Krapcho M. SEER Cancer Statistics Revie w, 1975-2011, 
National Cancer Institute, Bethesda, MD, http://seer.can cer.gov/csr/1975_2011/ , based on 
November 2013 SEER data submission. 
3. NCCN Guidelines for Lung Cancer. 4. Katayama R, Kobayashi Y, Friboul et L, Lockerman EL, Koike S,  Shaw AT, et al. 
Cabozantinib overcomes c rizotinib resistance in ROS1 fusion-pos itive cancer. Clinical 
cancer research : an official jour nal of the Ame rican Associati on for Cancer Research. 
2015;21(1):166-74. 
5. Shaw AT, Ou SH, Bang YJ, Cami dge DR, Solomon BJ, Salgia R, e t al. Crizotinib in 
ROS1-rearranged non-small-cell lu ng cancer. The New England jou rnal of medicine. 
2014;371(21):1963-71. 
6. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Go ksel T, et al. 
Ramucirumab plus docetaxel versus placebo plus docetaxel for se cond-line treatment of 
stage IV non-small-cel l lung cancer after disease progression o n platinum-based therapy 
(REVEL): a multicentre, double- blind, randomised phase 3 trial.  Lancet (London, 
England). 2014;384(9944):665-73. 
7. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready N E, et al. Nivolumab 
versus Docetaxel in Advanced N onsquamous Non-Small-Cell Lung Ca ncer. The New 
England journal of medic ine. 2015;373(17):1627-39. 
8. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddub skaya E, et al. 
Nivolumab versus Docetaxel in A dvanced Squamous-Cell Non-Small- Cell Lung Cancer. 
The New England journal of  medicine. 2015;373(2):123-35. 
9. Herbst RS, Baas P, Kim DW, Fe lip E, Perez-Gracia JL, Han JY,  et al. Pembrolizumab 
versus docetaxel for previously treated, PD-L1-positive, advanc ed non-small-cell lung 
cancer (KEYNOTE-010): a randomise d controlled trial. Lancet (Lo ndon, England). 2015. 
10. Garon EB, Rizvi NA, Hui R, L eighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab 
for the treatment of  non-small-cell lung can cer. The New Englan d journal of medicine. 
2015;372(21):2018-28. 
11. Disis ML. Immune regulation of  cancer. Journal of clinical oncology : official journal of 
the American Society of C linical Oncology. 2010;28(29):4531-8. 
12. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. 
Adoptive cell transfer therapy f ollowing non-myeloablative but lymphodepleting 
chemotherapy for the treatment of  patients with refractory meta static melanoma. Journal 
of clinical oncology : official journal of the American Society  of Clinical Oncology. 
2005;23(10):2346-57. 
13. Hunder NN, Wallen H, Cao J, He ndricks DW, Reilly JZ, Rodmyr e R, et al. Treatment of 
metastatic melanoma with autologou s CD4+ T cells against NY-ESO -1. The New 
England journal of medic ine. 2008;358(25):2698-703. 
14. Greenwald RJ, Freeman GJ, Sha rpe AH. The B7 family revisite d. Annual review of 
immunology. 2005;23:515-48. 
15. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits 
B cell receptor-mediated signaling by recruiting src homology 2 -domain-containing 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 64 of 66 tyrosine phosphatase 2 to phosphotyr osine. Proceedings of the N ational Academy of 
Sciences of the United States  of America. 2001;9 8(24):13866-71.  
16. Zhang X, Schwartz JC, Guo X, B hatia S, Cao E, Lorenz M, et al. Structural and 
functional analysis of the cost imulatory receptor programmed de ath-1. Immunity. 
2004;20(3):337-47. 
17. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1  and SHP-2 associate 
with immunoreceptor tyrosine-based switch motif of programmed d eath 1 upon primary 
human T cell stimulation, but onl y receptor ligation prevents T  cell activation. Journal of 
immunology (Baltimore, M d : 1950). 2004;173(2):945-54. 
18. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooter s J, et al. PD-1 inhibits 
T-cell receptor induced phosphoryl ation of the ZAP70/CD3zeta si gnalosome and 
downstream signaling to PKCthe ta. FEBS letters. 2004;574(1-3):3 7-41. 
19. Riley JL. PD-1 signaling in pr imary T cells. Immunological reviews. 2009;229(1):114-
25. 
20. Parry RV, Chemnitz JM, Frauw irth KA, Lanfranco AR, Braunste in I, Kobayashi SV, et 
al. CTLA-4 and PD-1 receptors i nhibit T-cell activation by dist inct mechanisms. 
Molecular and cellular biology. 2005;25(21):9543-53. 
21. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in toler ance and autoimmunity. 
Immunological rev iews. 2010;236:219-42. 
22. Agata Y, Kawasaki A, Nishimu ra H, Ishida Y, Tsubata T, Yagi ta H, et al. Expression of 
the PD-1 antigen on the surface  of stimulated mouse T and B lym phocytes. International 
immunology. 1996;8(5):765-72. 
23. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR.  Activation-induced 
expression of human programmed de ath-1 gene in T-lymphocytes. E xperimental cell 
research. 1997;232(1):25-8. 
24. Nishimura H, Honjo T, Minato N . Facilitation of beta select ion and modification of 
positive selection in the thymus of PD-1-deficient mice. The Jo urnal of experimental 
medicine. 2000;191(5):891-8. 
25. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR,  et al. Blockade of 
programmed death-1 ligands on dendr itic cells enhances T cell a ctivation and cytokine 
production. Journal of immunol ogy (Baltimore, Md : 1950). 2003; 170(3):1257-66. 
26. Dong H, Strome SE, Salomao DR , Tamura H, Hirano F, Flies DB , et al. Tumor-
associated B7-H1 promotes T-cell apoptosis: a pote ntial mechani sm of immune evasion. 
Nature medicine. 2002;8(8):793-800. 
27. Sharpe AH, Freeman GJ. The  B7-CD28 superfamily. Nature revi ews Immunology. 
2002;2(2):116-26. 
28. Thompson RH, Dong H, Lohse CM, L eibovich BC, Blute ML, Chev ille JC, et al. PD-1 is 
expressed by tumor-infiltrating i mmune cells and is associated with poor outcome for 
patients with renal cell carcinoma. Clinical cancer research : an official jour nal of the 
American Association for Ca ncer Research. 2007;13(6):1757-61. 
29. Nomi T, Sho M, Akahori T, Ham ada K, Kubo A, Kanehiro H, et al. Clinical significance 
and therapeutic potential of the  programmed death-1 ligand/prog rammed death-1 
pathway in human pancreatic can cer. Clinical cancer research : an official jour nal of the 
American Association for Ca ncer Research. 2007;13(7):2151-7. 
30. Gao Q, Wang XY, Qiu SJ, Yamat o I, Sho M, Nakajima Y, et al.  Overexpression of PD-
L1 significantly associates wit h tumor aggressiveness and posto perative recurrence in 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 65 of 66 human hepatocellular carcinoma. C linical cancer research : an o fficial journal of the 
American Association for Can cer Research. 2009;15(3):971-9. 
31. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yama guchi K, et al. 
Programmed cell death 1 liga nd 1 and tumor-infiltrating CD8+ T lymphocytes are 
prognostic factors of human ovarian cancer. Proceedings of the National Academy of 
Sciences of the United States  of America. 2007;1 04(9):3360-5. 
32. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et  al. PD-1 is a regulator of 
NY-ESO-1-specific CD8+ T cell ex pansion in melanoma patients. J ournal of 
immunology (Baltimore, M d : 1950). 2009;182(9):5240-9. 
33. Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ. PD-1 ligands, 
negative regulators for activ ation of naive, memory, and recent ly activated human CD4+ 
T cells. Cellular immunology. 2004;230(2):89-98. 
34. Blank C, Mackensen A. Contri bution of the PD-L1/PD-1 pathwa y to T-cell exhaustion: 
an update on implications for chr onic infections and tumor evas ion. Cancer immunology, 
immunotherapy : CII. 2007;56(5):739-45. 
35. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. I nvolvement of PD-L1 on 
tumor cells in the escape from hos t immune system and tumor imm unotherapy by PD-L1 
blockade. Proceedings of the National Academy of Sciences of th e United States of 
America. 2002;99(19):12293-7. 
36. Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K , et al. Predominant 
expression of B7-H1 and its immuno regulatory roles in oral squa mous cell carcinoma. 
Oral oncology. 2006;42(3):268-74. 
37. Papadimitrakopoulou V, Patnai k A, Borghaei H, Stevenson J, Gandhi L, Gubens M, et al. 
Pembrolizumab (pembro; MK-3475 ) plus platinum doublet chemother apy (PDC) as 
front-line therapy for advance d non-small cell lung cancer (NSC LC): KEYNOTE-021 
Cohorts A and C. . J Clin Onc ol (suppl; abst 8031). 2015. 
38. Antonia S, Brahmer J, Gettinger SN, Chow LQ, Juergens R, Sh epherd FA, et al. 
Nivolumab (Anti-PD-1;BMS-936558, ONO-4538) in Combination with Platinum-Based 
Doublet Chemotherapy (PT-DC) i n Advanced Non-Small Cell Lung Ca ncer (NSCLC). 
International Journal of Rad iation Oncology. 2014;90(5 (supplem ent)):S2. 
39. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de  Jongh FE, et al. 
Trastuzumab beyond progression in human epidermal growth factor  receptor 2-positive 
advanced breast cancer: a germ an breast group 26/ breast interna tional group 03-05 study. 
Journal of clinical oncology : offi cial journal of the American  Society of Clinical 
Oncology. 2009;27(12):1999-2006. 
40. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick  E, et al. Bevacizumab 
beyond first progression is asso ciated with prolonged overall s urvival in metastatic 
colorectal cancer: re sults from a la rge observational cohort st udy (BRiTE). Journal of 
clinical oncology : official journa l of the American Society of  Clinical Oncology. 
2008;26(33):5326-34. 
41. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame J N, et al. Systemic 
therapy in men with met astatic castration-resistant prostate ca ncer:American Society of 
Clinical Oncology and Cancer Car e Ontario clini cal practice gui deline. Journal of clinical 
oncology : official jour nal of the America n Society of Clinical  Oncology. 
2014;32(30):3436-48. 
Big Ten Cancer Research Consor tium   Clinical Study Protocol 
    BTCRC-LUN15-029  
07NOV2019 Confidential Page 66 of 66 42. Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA,  et al. Randomized Phase 
II Trial of Erlotinib Beyond Pr ogression in Advan ced Erlotinib- Responsive Non-Small 
Cell Lung Cancer. The oncologist. 2015;20(11):1298-303. 
43. Shepherd FA, Dancey J, Ramla u R, Mattson K, Gralla R, O'Rou rke M, et al. Prospective 
randomized trial of docetaxel vers us best supportive care in pa tients with non-small-cell 
lung cancer previously treated w ith platinum-based chemotherapy . Journal of clinical 
oncology : official jour nal of the America n Society of Clinical  Oncology. 
2000;18(10):2095-103. 
44. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunp hy F, et al. Randomized 
phase III trial of docet axel versus vinorelbin e or ifosfamide i n patients with advanced 
non-small-cell lung cancer previ ously treated with platinum-con taining chemotherapy 
regimens. The TAX 320 Non-Sma ll Cell Lung Cancer Study Group. J ournal of clinical 
oncology : official jour nal of the America n Society of Clinical  Oncology. 
2000;18(12):2354-62. 
45. Hanna N, Shepherd FA, Fossella F V, Pereira JR, De Marinis F , von Pawel J, et al. 
Randomized phase III trial of peme trexed versus docetaxel in pa tients with non-small-
cell lung cancer previ ously treated with chemotherapy. Journal of clinical oncology : 
official journal of the America n Society of Clin ical Oncology. 2004;22(9):1589-97. 
 